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1. INTRODUCTION
1.1 DIABETES
Diabetes Mellitus (DM), often simply referred to as diabetes, is a group of
metabolic diseases in which a person is mainly characterized by hyperglycemia
either because of insulin deficiency or because of the resistance shown by the cells
to insulin produced in the body. It may also be characterized by glycosuria, negative
nitrogen balance, and sometimes ketonemia. This high blood sugar produces the
classical symptoms of polyuria (frequent urination), polydipsia (increased thirst) and
polyphagia (increased hunger).
Classification of Diabetes mellitus
Diabetes Mellitus is classified based on the cause or mode of treatments into the
following types:
1. Insulin-dependent diabetes mellitus (IDDM)
2. Non-insulin-dependent diabetes mellitus (NIDDM)
3. Gestational diabetes mellitus (GDM)
4. Secondary to other conditions
A) Type I (or)Insulin-dependent diabetes mellitus (IDDM)
Characterized by the body's failure to produce insulin due to the destruction of
β cells in the islets of langerhans, and  requires the person to inject insulin.
Formerly, it is known as "juvenile diabetes," because it represents a majority of the
cases in children, teenagers, or young adults, but it can also affect adults. Type-1
diabetes is mostly caused by autoimmune disorder AND develops because the body
immune system mistakenly destroys the beta cells in the islet tissue of the pancreas
that produce insulin due to environmental factors.
For the treatment of type I insulin must be given subcutaneously or by
injecting through any other novel routs of administration.
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B) Type II (or)Non-insulin-dependent diabetes mellitus (NIDDM)
Characterized by insulin resistance, a condition in which cells fail to use
insulin properly, sometimes combined with an absolute insulin deficiency. People
can develop type 2 diabetes at any age even during childhood. This form of diabetes
usually occurs because of abnormality in gluco receptor of β cells, Reduced
sensitivity of peripheral tissues to insulin, Excess of hyperglycemic hormones.
Insulin is not sufficient for the treatment of type II diabetes
Treatment includes (1) Agents which increase the amount of insulin secreted by the
pancreas, (2) Agents which increase the sensitivity of target organs to insulin, and
(3) Agents which decrease the rate at which glucose is absorbed from the
gastrointestinal tract.
C) Gestational diabetes mellitus (GDM)
Diabetes develops during pregnancy and mostly disappears after delivery.
During pregnancy, increased levels of certain hormones made in the placenta help
take nutrients from the mother to the developing fetus. Hormones from the placenta
help the baby develop. However, these hormones also block the action of the
mother's insulin in her body, called insulin resistance. Insulin resistance makes it
hard for the mother's body to use insulin. She may need up to three times as much
insulin.
D) Secondary to other conditions
Diabetes occurring  as secondary to the conditions like Pancreatic disease,
Hormonal disease, Drug or chemical exposure, Insulin receptor abnormalities,
certain genetic syndromes.
Signs and Symptoms :
The classical symptoms of diabetes are Polyuria (frequent urination),
Polydipsia (increased thirst) and Polyphagia (increased hunger). Symptoms may
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develop rapidly (weeks or months) in type 1 diabetes while in type 2 diabetes they
usually develop much more slowly.
People may also present with diabetic ketoacidosis, characterized by the smell of
acetone; a rapid, deep breathing known as Kussmaul breathing; nausea; vomiting
and abdominal pain; and altered states of consciousness.
Diagnosis
Table no – 01 Criteria for diagnosis of diabetes:
Epidemiology
According to recent estimates, approximately 285 million people worldwide
(6.6%) in the 20–79 year age group were having   diabetes in 2010 and by 2030, 438
million people (7.8%)of the adult population, is expected to have diabetes. The
largest increases will take place in the regions dominated by developing economies.
The global increase in the prevalence of diabetes is due to population growth,
aging, urbanization and an increase of obesity and physical inactivity. The three
countries with the largest number of people with diabetes are India, China and the
U.S with 50.8, 43.2, 26.8 million patients respectively.
2006 WHO Diabetes criteria[20]
Condition
2 hour glucose
mmol/l(mg/dl)
Fasting glucose
mmol/l(mg/dl)
Normal <7.8 (<140) <6.1 (<110)
Impaired Fasting
Glycaemia
<7.8 (<140) ≥ 6.1(≥110) &<7.0(<126)
Impaired Glucose
Tolerance
≥7.8 (≥140) <7.0 (<126)
Diabetes Mellitus ≥11.1 (≥200) ≥7.0 (≥126)
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Management
Diabetes mellitus is a chronic disease which cannot be cured except in very
specific situations. Management  keeps blood sugar levels as close to normal  as
possible, without causing hypoglycemia. This can usually be accomplished with
diet, exercise, and use of appropriate medications (insulin in the case of type 1
diabetes, oral antidiabetec  medications as well as possibly insulin in type 2
diabetes).
Oral Antidiabetec Drugs :
For treating type II diabetes many drugs are given through oral route of
administration, they are:
1. Insulin Sensitizers
i) Biguanides: Biguanides reduce hepatic glucose output and increase uptake of
glucose by the periphery, including skeletal muscle.
Examples: Metformin, Phenformin, Buformin
ii) Thiazolidinediones: Thiazolidinediones (TZDs), also known as "glitazones,  are
the agonists of peroxysome proliferator activated receptor PPARγ which enhances
the transcription of  insulin responsive genes. They tend to reverse the insulin
resistance.
Examples: Rosiglitazone , Pioglitazone, Troglitazone
2. Insulin Secretagogues
i) Sulfonylureas : They are insulin secretagogues, triggering insulin release by
inhibiting the KATP channel of the pancreatic beta cells. The "second-generation"
drugs are now more commonly used. They are more effective than first-generation
drugs and have fewer side effects. All may cause weight gain.
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First generation agents: Tolbutamide, Acetohexamide, Tolazamide,
Chlorpropamide .
Second generation agents: Glipizide, Glyburide, Glimepiride, Gliclazide .
ii) Meglitinides: Meglitinides help the pancreas produce insulin and are often called
"short-acting secretagogues." They act on the same potassium channels as
sulfonylureas, but at a different binding site.
Examples: Repaglinide (Prandin), Nateglinide (Starlix)
3. Alpha-Glucosidase Inhibitors:
Alpha-glucosidase inhibitors are  not technically hypoglycemic agents because
they do not have a direct effect on insulin secretion or sensitivity. These agents slow
the digestion of starch in the small intestine, so that glucose from the starch of a
meal enters the bloodstream more slowly. but can be helpful in combination with
other agents in type 2 diabetes.
Examples: Miglitol (Glyset), Acarbose (Precose/Glucobay).
Novel Oral Antidiabetecs
Dipeptidyl  Peptidase (DPP)-4 Inhibitors
DPP4 inhibitors such as Sitagliptin and Vildagliptin are novel agents for
treatment of type 2 diabetes. They work by improving β-cell sensitivity to glucose,
whereby it increases glucose-dependent insulin secretion. Gliptins can be used as
monotherapy or combined with metformin or SUs. Gliptins are largely weight
neutral.
Examples: Sitagliptin, Vidagliptin.
Combination therapy
However, with disease progression, in most instances, monotherapy loses
efficacy over time as evidenced by a continued increase in HbA1c. In addition to
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insulin resistance, β-cell dysfunction plays a key role in the progression of T2DM.
the primary objective of combining oral antidiabetic treatments for T2DM is to
address the dual problems of insulin deficiency and insulin resistance.
Metformin - The most widely used Oral Antidiabetic
Metformin, a biguanide that acts directly against insulin resistance, is
regarded as an insulin sensitizing drug and is considered to be a cornerstone in the
treatment of T2DM. Because of its safety and efficacy, Metformin can be initiated as
first line monotherapy unless a contraindication such as renal disease, hepatic
disease, gastrointestinal intolerance or risk of lactic acidosis coexists.[4] Amongst
common diabetic drugs, Metformin is the only widely used oral drug that does not
cause weight gain.
Despite being the most widely used OAD in the world, metformin can reach a
plateau of effectiveness due to progressive β-cell failure.[34,35] Thus Metformin also
forms the cornerstone of dual therapy and is used extensively in combination with
several classes of OADs like
i)Sulphonylurea Ex: Glipizide (Metaglip®), Gliclazide, Glibenclamide
(Glucovance®),
ii) Glitazones Ex: Rosiglitazone (Avandamet®), Pioglitazone (Actoplus Met®),
iii) Meglitinides Ex : Repaglinide (Prandimet®).
iv) DPP-4 Inhibitors   Ex: Sitagliptin (Janumet®),
In recent meta-analyses, Rao et al. have shown that combination therapy with
metformin and SUs significantly increased the relative risk of cardiovascular
hospitalization or mortality
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Metformin Sitagliptin Combination
Metformin Sitagliptin Combination is used when  initial therapy in patients
with type 2 diabetes mellitus to improve glycemic control when diet and exercise do
not provide adequate glycemic control.
Combination is indicated as an adjunct to diet and exercise to improve glycemic
control in patients with type 2 diabetes mellitus inadequately controlled on
metformin or sitagliptin alone or in patients already being treated with the
combination of sitagliptin and metformin
1.2 ORAL DOSAGE FORMS
Oral drug delivery is the most widely utilized route of administration among
all the routes that have been explored for systemic delivery of drugs through
different dosage forms. Oral route is considered most natural, uncomplicated,
convenient and safe due to its ease of administration, patient acceptance and cost-
effective manufacturing process1.
Pharmaceutical products designed for oral delivery are mainly conventional
drug delivery systems, which are designed for immediate release of drug for rapid
absorption. These immediate release dosage forms have some limitations such as2, 3:
1) Drugs with short half-life require frequent administration, which increase the
chances of missing dose of drug leading to poor patient compliance.
2) A typical peak-valley plasma concentration-time profile is obtained which
makes it difficult to attainment of steady state condition.
3) The unavoidable fluctuations in the drug concentration may lead to under
medication or overmedication as the CSS values fall or rise beyond the
therapeutic range.
4) The fluctuating drug levels may lead to precipitation of adverse effects
especially of a drug with small therapeutic index, whenever overmedication
occurs.
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In order to overcome the drawbacks of conventional drug deliver systems,
several technical advancements have led to the development of controlled drug
delivery system that could revolutionize method of medication and provide a
number of therapeutic benefits4.
1.3 Controlled Drug Delivery Systems
Controlled drug delivery systems have been developed which are capable of
controlling the rate of drug delivery, sustaining the duration of therapeutic activity
and/or targeting the delivery of drug to a tissue5.
Controlled drug delivery or modified drug delivery systems are conveniently
divided into four categories.
1) Delayed release
2) Sustained release
3) Site-specific targeting
4) Receptor targeting
More precisely, Controlled delivery can be defined as6: -
1) Sustained drug action at a predetermined rate by maintaining a relatively
constant, effective drug level in the body with concomitant minimization of
undesirable side effects.
2) Localized drug action by spatial placement of a controlled release system
adjacent to or in the diseased tissue.
3) Targeted drug action by using carriers or chemical derivatives to deliver drug
to a particular target cell type.
4) Provide a physiologically/therapeutically based drug release system. In other
words, the amount and the rate of drug release are determined by the
physiological/ therapeutic needs of the body.
A controlled drug delivery system is usually designed to deliver the drug at
particular rate. Safe and effective blood levels are maintained for a period as long as
the system continues to deliver the drug. Controlled drug delivery usually results in
substantially constant blood levels of the active ingredient as compared to the
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uncontrolled fluctuations observed when multiple doses of quick releasing
conventional dosage forms are administered to a patient.
Advantages of Controlled Drug Delivery System7
1. Avoid patient compliance problems.
2. Dosage frequency were reduced
a) Minimize or eliminate local side effects
b) Minimize or eliminate systemic side effects
c) Obtain less potentiation or reduction in drug activity with chronic use.
d) Minimize drug accumulation with chronic dosing.
3. Improve efficiency in treatment
a) Cures or controls condition more promptly.
b) Improves control of condition i.e., reduced fluctuation in drug level.
c) Improves bioavailability of some drugs.
d) Make use of special effects, eg. Sustained-release aspirin for morning relief
of arthritis by dosing before bedtime.
4. Economy i.e. reduction in health care costs. The average cost of treatment over
an extended time period may be less, with less frequency of dosing, enhanced
therapeutic benefits and reduced side effects. The time required for health care
personnel to dispense and administer the drug and monitor patient is also
reduced
Disadvantages
1) Decreased systemic availability in comparison to conventional dosage
forms, which may be due to incomplete release, increased first-pass
metabolism, increased instability, insufficient residence time for complete
release, site specific absorption, pH dependent stability etc.
2) Poor in vitro – in vivo correlation.
3) Possibility of dose dumping due to food, physiologic or formulation
variables or chewing or grinding of oral formulations by the patient and
thus, increased risk of toxicity.
4) Retrievals of drug are difficult in case of toxicity, poisoning or
hypersensitivity reactions.
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5) Reduced potential for dosage adjustment of drugs normally administered in
varying strengths.
Oral Controlled Drug Delivery Systems
Oral controlled release drug delivery is a drug delivery system that provides
the continuous oral delivery of drugs at predictable and reproducible kinetics for a
predetermined period throughout the course of GI transit and also the system that
target the delivery of a drug to a specific region within the GI tract for either local or
systemic action.
Therefore the scientific framework required for the successful development of oral
drug delivery systems consists of basic understanding of (i) Physicochemical,
pharmacokinetic and pharmacodynamic characteristics of the drug (ii) the anatomic
and physiologic characteristics of the gastrointestinal tract and (iii) physicochemical
characteristics and the drug delivery mode of the dosage form to be designed.
The main areas of potential challenge in the development of oral controlled drug
delivery systems are: -
1) Development of a drug delivery system: To develop a viable oral controlled
release drug delivery system capable of delivering a drug at a therapeutically
effective rate to a desirable site for duration required for optimal treatment.
2) Modulation of gastrointestinal transit time: To modulate the GI transit time
so that the drug delivery system developed can be transported to a target site
or to the vicinity of an absorption site and reside there for a prolonged period
of time to maximize the delivery of a drug dose.
3) Minimization of hepatic first pass elimination: If the drug to be delivered is
subjected to extensive hepatic first-pass elimination, preventive measures
should be devised to either bypass or minimize the extent of hepatic
metabolic effect.
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1.4 GASTRO  RETENTIVE  DRUG  DELIVERY  SYSTEM (GRDDS)
These are the controlled drug delivery systems, with a prolonged residence
time in the stomach. A major constraint in oral CRDD is that not all drug candidates
are absorbed uniformly throughout the gastrointestinal tract. Some drugs are
absorbed uniformly throughout the Gastro intestinal tract. Some drugs are absorbed
in a particular portion of gastrointestinal tract only or are absorbed to a different
extent in various segments of gastrointestinal tract. Such drugs are said to have an
“absorption window”. Thus, only the drug released in the region preceding and in
close vicinity to the absorption window is available for absorption.
Generally gastroretention was done for:
 To control (or) increase the gastric residence time (GRT).
 To delay the gastric emptying process.
Suitable Drug Candidates For Gastroretention
 Drugs that are absorbed from the proximal part of the gastrointestinal tract i.e
absorption window present in upper part of the GIT . examples: Sulphonamides,
Quinolones, Penicillin’s, Cephalosporin’s, amino glycosides, Tetracycline’s
etc.
 For sparingly soluble and insoluble drugs the solubility can be increased by
increasing their gatric residence time there by improving bioavailability.
 Drugs that are degraded by the alkaline pH they encounter at the lower part of GIT.
 GRDFs greatly improve the pharmacotherapy of the stomach through local
drug release, leading to high drug concentration at the gastric
mucosa.Particularly useful for the treatment of peptic ulcers caused by H. pylori
infections.
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Different Techniques Of Gastric Retention
Various techniques were used to encourage gastric retention of an oral dosage form
 High density systems:
 Floating Drug delivery systems
 Non-Effervescent systems
- Hydrodynamically balanced systems (HBS):
 Effervescent systems
- Gas generating Systems :
- Low-density systems:
- Raft systems incorporate alginate gels:
 Expandable Systems:
 Superporous Hydrogels
 Bioadhesive or mucoadhesive systems:
 Magnetic Systems
Among the available techniques from the formulation and technological point of view, the
floating drug delivery system is considerably easy and logical approach.
1.5 FLOATING DRUG DELIVERY SYSTEMS
The concept of FDDS was described in the literature as early as 1962. Floating drug
delivery systems (FDDS) have a bulk density less than gastric fluids and so remain
buoyant in the stomach without affecting the gastric emptying rate for a prolonged
period of time. While the system is floating on the gastric contents, the drug is
released slowly at the desired rate from the system. After release of drug, the
residual system is emptied from the stomach. This results in an increased GRT and a
better control of fluctuations in plasma drug concentration
Formulation of this device must comply with the following criteria:
1. It must have sufficient structure to form a cohesive gel barrier.
2. It must maintain an overall specific gravity lower than that of gastric contents
(1.004 –1.010).
3. It should dissolve slowly enough to serve as a drug reservoir.
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Classification of floating drug delivery systems (FDDS)
Based on the mechanism of buoyancy, two distinctly different technologies, i.e.
non effervescent and effervescent systems, have been utilized in the development of
FDDS.
A. Effervescent Floating Dosage Forms
i) Gas Generating Systems
a) Intra Gastric Single Layer Floating Tablets or Hydro dynamically Balanced
System (HBS): These are as shown in Fig.01 and formulated by intimately mixing
the CO2 generating agents and the drug within the matrix tablet.   These have a bulk
density lower than gastric fluids and therefore remain floating in the stomach
unflattering the gastric emptying rate for a prolonged period. The drug is slowly
released at a desired rate from the floating system and after the complete release the
residual system is expelled from the stomach. This leads to an increase in the GRT
and a better control over fluctuations in plasma drug concentration.
Fig 01: Intra Gastric Single Layer Buoyant Tablet.
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b) Intra Gastric Bilayer Floating Tablets
These are also compressed tablet as shown in Fig 9 and containing two layers i.e.,
i. Immediate release layer and
ii. Sustained release layer.
Fig 02:  Intra Gastric Bilayer Buoyant Tablet.
c) Multiple Unit type floating pills
These systems consist of sustained release pills as ‘seeds’ surrounded by
double layers. The inner layers consist of effervescent agents while the outer layer is
of swellable membrane layer. When the system is immersed in dissolution medium
at body temperature, it sinks at once and then forms swollen pills like balloons,
which float as they have lower density. This lower density is due to generation and
entrapment of CO2 within the system.
Fig 03: A multi-unit oral buoyant dosage system (a) conventional SR pills; (b)
effervescent layer; (c) swellable layer; (d) expanded swellable membrane layer;
(e) surface of water in the beaker (370C)
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ii) Volatile Liquid / Vacuum Containing Systems
a) Intragastric Floating Gastrointestinal Drug Delivery System
These systems can be made to float in the stomach because of floatation chamber,
which may be a vacuum or filled with air or a harmless gas, while drug reservoir is
encapsulated inside a micro porous compartment, as shown in Fig  04.
Fig 04: Intra Gastric Floating Gastrointestinal Drug Delivery Device
b) Inflatable Gastrointestinal Delivery Systems
In these systems an inflatable chamber is incorporated, which contains liquid ether
that gasifies at body temperature to cause the chamber to inflate in the stomach.
These systems are fabricated by loading the inflatable chamber with a drug
reservoir.
Fig 05: Inflatable Gastrointestinal Delivery System
After oral administration, the capsule dissolves to release the drug reservoir
together with the inflatable chamber. The inflatable chamber automatically inflates
and retains the drug reservoir compartment in the stomach. The drug continuously
released from the reservoir into the gastric fluid. This system is shown in Fig  05.
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c) Intragastric Osmotically Controlled Drug Delivery System
It is comprised of an osmotic pressure controlled drug delivery device and an
inflatable floating support in a biodegradable capsule. In the stomach, the capsule
quickly disintegrates to release the intragastirc osmotically controlled drug delivery
device. The inflatable support inside forms a deformable hollow polymeric bag that
contains a liquid that gasifies at body temperature to inflate the bag. The osmotic
pressure controlled drug delivery device consists of two components; drug reservoir
compartment and an osmotically active compartment. The floating support is also
made to contain a bio erodible plug that erodes after a predetermined time to deflate
the support. The deflated drug delivery system is then emptied from the stomach.
This system is shown in Fig  06.
Fig  06:  Intragastric Osmotically Controlled Drug Delivery System
iii) Raft-forming systems
Here, a gel-forming solution (e.g. sodium alginate solution containing carbonates or
bicarbonates) swells and forms a viscous cohesive gel containing entrapped CO2
bubbles (Fig. 6) on contact with gastric fluid. Formulations also typically contain
antiacids such as aluminium hydroxide or calcium carbonate to reduce gastric
acidity. Because raft-forming systems produce a layer on the top of gastric fluids,
they are often used for gastroesophageal reflux treatment as with Liquid Gaviscon\
(GlaxoSmithkline).
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B. NON-EFFERVESCENT SYSTEMS
The Non-effervescent FDDS based on mechanism of swelling of polymer or
bioadhesion to mucosal layer in GI tract. The most commonly used excipients in
non-effervescent FDDS are gel forming or highly swellable cellulose type
hydrocolloids, polysaccharides and matrix forming material such as Polycarbonate,
Polyacrylate, Polymethacrylate, polystyrene as well as bioadhesive polymer such as
Chitosan and Carbopol. The various types of this system are as:
a) Single Layer Floating Tablets
They are formulated by intimate mixing of drug with a gel-forming hydrocolloid,
which swells in contact with gastric fluid and maintain bulk density of less than
unity. The air trapped by the swollen polymer confers buoyancy to these dosage
forms.
b) Bilayer Floating Tablets
A bilayer tablet contain two layer one immediate release layer which release
initial dose from system while the another sustained release layer absorbs gastric
fluid, forming an impermeable colloidal gel barrier on its surface, and maintain a
bulk density of less than unity and thereby it remains buoyant in the stomach.
c) Alginate Beads
Multi unit floating dosage forms were developed from freeze-dried calcium alginate.
Spherical beads of approximately 2.5 mm diameter can be prepared by dropping a
sodium alginate solution into aqueous solution of calcium chloride, causing
precipitation of calcium alginate leading to formation of porous system, which can
maintain a floating force for over 12 hours.
d) Hollow Microspheres
Hollow microspheres (micro balloons), loaded with drug in their outer
polymer shells were prepared by a novel emulsion-solvent diffusion method. The
ethanol: dichloromethane solution of the drug and an enteric acrylic polymer was
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poured into an agitated aqueous solution of PVA that was thermally controlled at
400C. The gas phase generated in dispersed polymer droplet by evaporation of
dichloromethane formed an internal cavity in microsphere of polymer with drug.
The micro balloons floated continuously over the surface of acidic dissolution media
containing surfactant for more than 12 hours in vitro.
Fig  07: Hallow microspheres
1.6  BILAYER TABLETS
Multi - Layer Tablets
Layer tablets are composed of two or three layers of granulation compressed
together. They have the appearance of a sandwich because the edges of each layer
are exposed13. This dosage form has the advantages of separating two incompatible
substances with an inert barrier between them and possibility of sustained- release
from one portion. The weight of each layer can be accurately controlled, in contrast
to putting one drug of a combination product in a sugar coating.. Coloring the
separate layers provide many possibilities for unique tablets identity. Analytical
work may be simplified by a separation of the layers prior to assay.
Bilayer Tablet is a new era for the successful development of controlled
release formulation along with various features to provide a way of successful drug
delivery system.these are the dosage forms having two active ingredients  present as
two distinct separate layers compressed into a tablet.
Bi-layer tablets are prepared with one layer of drug for immediate release
while second layer designed to release drug, later, either as second dose or in an
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extended release manner. Bi-layer tablet is suitable for sequential release of two
drugs in combination. To separate two incompatible substances and also for
sustained release tablet in which one Layer is immediate release as initial dose and
second layer is maintenance dose.
Various Techniques for Bi Layer Tablet
A) OROS® push pull technology
This system consist of mainly two or three layer among which the one or more
layer are essential of the drug and other layer are consist of push layer. The drug
layer mainly consists of drug along with two or more different agents. So this drug
layer comprises of drug which is in poorly soluble form. There is further addition of
suspending agent and osmotic agent. A semi permeable membrane surrounds the
tablet core.
Fig no – 08: Bilayer and trilayer OROS Push pull technology
B) L-OROS tm technology
This system used for the solubility issue Alza developed the L-OROS system
where a lipid soft gel product containing drug in a dissolved state is initially
manufactured and then coated with a barrier membrane, than osmotic push layer and
than a semi permeable membrane, drilled with an exit orifice.
Figure 09: L – OROS tm technology
Chapter 1 Introduction
Bilayer Floating Tablets Of Metformin Hcl And Sitagliptin Phosphate Page 20
C) EN SO TROL Technology
Solubility enhancement of an order of magnitude or to create optimized dosage
form Shire laboratory use an integrated approach to drug delivery focusing on
identification and incorporation of the identified enhancer into controlled release
technologies
Figure 10 : EN SO TROL Technology
D) DUROS Technology
The system consists from an outer cylindrical titanium alloy reservoir. This
reservoir has high impact strength and protects the drug molecules from enzymes.
The DUROS technology is the miniature drug dispensing system that opposes like a
miniature syringe and reglious minute quantity of concentrated form in continues
and consistent from over months or year.
E) Elan.Drug.Technologies’.Dual Release Drug Delivery System
(DUREDAS™ Technology) is a bilayer tablet which can provide immediate
or sustained release of two drugs or different release rates of the same drug in one
dosage form. The tableting process can provide an immediate release granulate and
a modified-release hydrophilic matrix complex as separate layers within the one
tablet. The modified-release properties of the dosage form are provided by a
combination of hydrophilic polymers.
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Benefits offered by the DUREDAS™ technology include
1) Bilayer.tabletting.technology.
2) Tailored.release.rate.of.two.drug.components.
3) Capability.of.two.different.CR.formulations.combined.
4) Capability for immediate release and modified release components in one tablet.
5) Unit.dose,tablet.presentation
Bi-layer Tablets: Quality and GMP-Requirements
To produce a quality bi-layer tablet, in a validated and GMP-way, it is important that
the selected press is capable of:
 Preventing capping and separation of the two individual layers that
constitute the bi-layer tablet
 Providing sufficient tablet hardness
 Preventing cross-contamination between the two layers
 Producing a clear visual separation between the two layers
 High yield
 Accurate and individual weight control of the two layers these
requirements seem obvious but are not as easily accomplished as
this article aims to demonstrate
Limitations  of The Single Sided Press Bi-Layer Tablets
 No weight monitoring/control of the individual Layers.
 No distinct visual separation between the two Layers.
 Very short first layer-dwell time due to the small compression roller,
possibly resulting in poor de-aeration, capping and hardness problems. This
may be corrected by reducing the turret-rotation speed (to extend the dwell
time) but with the consequence of lower tablet.output.
 Very difficult first-layer tablet sampling and sample transport to a test unit
for in-line quality control and weight recalibration to eliminate these
limitations, a double-sided tablet press is preferred over a single-sided press.
A double-sided press offers an individual fill station, pre -compression and
main compression for each layer.
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Different attempts made by scientists for preparation of bilayer
formulations
 Linhong et al., developed that the metformin hydrochloride has synergistic
effect with glimepiride; the medicine comp has the advantage of reduced
dose of each ingredient equivalent curative effect to single ingredient
medicine and convenient administration.
 Wagstaff et al., developed that the metformin is released at a controlled rate
from a central osmotic tablet core through a semi permeable coating. A
decrease in fasting plasma insulin, a marker of insulin resistance was seen
with metformin extended release but not with immediate release. It shows
that the metformin extended release given in the single dose is equal to the
metformin immediate release given in the divided dose.
 Chawla et al., developed the combination of the biguanide and a
sulfonylurea. It provides the extended release of both the drugs i.e.
Metformin and Glipizide.
 Kesarwani et al., developed an oral solid dosage form that includes a
combination of a biguanide as an extended release phase and a sulfonylurea
as an immediate release coating form. A tablet was formulated which
contains core material as metformin hydrochloride by using HPMC as a
polymer ; seal coating; then coating of glimepiride by using HPMC as a
polymer; then film coating was done.
 Shanghvi et al., developed that spaced drug delivery system release two or
more antidiabetic agents at different times after oral administration, for the
treatment of diabetic mellitus. The delayed release metformin hydrochloride
core prepared by granulation and compression of ingredients was mixed with
the immediate release glipizide granules and encapsulated in hard gelatin
capsules.
 Amit Kumar et al., developed orally administrated extended release
pharmaceutical compounds that include a combination of a highly water
soluble high dose (i.e. 500 mg) biguanide  (metformin hydrochloride)and a
water insoluble low dose (2 mg) sulfonylurea in a extended release bilayered
dosage form.
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 Tang et al., developed the metformin and glimepiride which can decrease
free fatty acid levels, body weight index, blood glucose and insulin
resistance. Free fatty level can reflect the index of insulin resistance to some
degree.
1.7 Hydrophilic Polymers In Controlled Drug Delivery
The prototypes of orally administered hydrophilic matrices were first
described more than 4 decades ago, and since then, a number of ER technologies
have been developed and registered. From a commercial perspective, hydrophilic
matrices are economical to develop and manufacture due to the use of available
equipment without further investment, stable formulations, and broad regulatory
acceptance. In most instances, hydrophilic matrices use polymers with flexible
chemistry that offer an opportunity to formulate an ER dosage form for a wide range
of APIs with varying solubility and doses.
Various high molecular weight, water soluble or water-swellable polymers have
been used in hydrophilic matrices, such as Hypromellose [hydroxypropyl
methylcellulos, HPMC], Hydroxyl propyl cellulose, Sodium carboxy methyl
cellulose, Sodium alginate, Carbomers, and Polyethylene oxide
HPMC, by far, is the most popular polymer in matrix applications because of its
ability to obtain desired release profiles for a wide range of drugs, provide robust
formulation, global availability, cost-effective manufacture, broad regulatory
acceptance, and extensive history on its use.
Although the use of HPMC as a rate controlling hydrophilic polymer in ER
formulations is well-documented, the following are still some unmet needs and
challenges associated with ER hydrophilic matrices:
 HPMC is a nonionic polymer and hence the matrices exhibit pH independent
drug release profiles when drug solubility is pH independent. However,
when drug solubility is pH-dependent, eg, for Superdisintegrants : HPMC
matrices may exhibit an initial burst release for very soluble drugs.This
behavior has been attributed to the rapid dissolution of the drug from the
surface and near the surface of the matrix, while the polymer undergoes
hydration to form a protective gel layer.
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 Developing an ER hydrophilic matrix formulation of high dose APIs (eg 500
to 1000 mg) is challenging because of overall restrictions on size of the
tablets for ease of swallowing.
 ER hydrophilic matrix formulations of very slightly soluble or practically
insoluble drugs may exhibit food effects, ie, variable bioavailability,
depending on administration during fasting or fed state.
COMBINATION OF HPMC WITH  OTHER POLYMERS
HPMC is a nonionic water soluble polymer, and hence, the possibility of
chemical interaction or complexation with other formulation components is greatly
reduced, and the hydration and gel formation of its matrices are pH-independent.
Thus HPMC is typically used as the primary polymer, and other approved
polymer(s) have been added to enhance functionality and as a tool to modulate the
drug release profile. Here, blends of HPMC with other polymers, including ionic,
nonionic, and water-insoluble polymers, are discussed.
Drug solubility is an important factor determining the mechanism of drug
release from HPMC hydrophilic matrices. Practically insoluble drugs (Eg, solubility
< 0.01 mg/mL) may dissolve slowly and have slow diffusion through the gel layer of
a hydrophilic matrix. Therefore, the main mechanism of release would be through
surface erosion of the hydrated matrix. In these cases, the control over matrix
erosion to achieve consistent ER throughout the GI tract is critical, hence, low
viscosity grades of HPMC (Eg, METHOCEL Premium K100LV or E50LV) that
provide adequate erosion are recommended.
For drugs with very high water solubility, the drug dissolves within the gel
layer (even with small amounts of free water) and diffuses out into the media.
Therefore, it is important to ensure integrity of the gel layer after the drug has been
dissolved and released from the gel layer. In this case, it is critical to have a strong
gel layer through which diffusion can occur and hence, high viscosity grades of
HPMC (METHOCEL Premium K4M, K15M, or K100M) are recommended in their
formulations.
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The strategy of blending high- and low viscosity grades of HPMC has
also been reported for achieving the zero-order release profile from matrix
formulations and for reducing the drug release variability (low % Relative Standard
Deviation, % RSD), thereby providing more uniform clinical levels of the drug.
HPMC  With Poly Methacrylates
Combination of HPMC and poly methacrylates, most notably anionic
polymers (Eudragit L100 55) in hydrophilic matrices, has been reported for
developing pH-independent release profiles for weakly basic drugs. Combining of
Eudragit E 100 with HPMC matrices has been shown to result in pH-independent
release for acidic drugs, such as Divalproex sodium. This effect has been attributed
to the enhanced solubility and hence, release of the drug in acidic media and
retardation of the drug release in basic media.
HPMC With Poly Vinyl Acetate Phthalate
Poly Vinyl Acetate Phthalate is another enteric polymer used in combination
with HPMC to control the micro enviornmental pH and enhance matrix properties,
such as gel strength and erosion. Combining PVAP with HPMC to formulate
matrices containing verapamil hydrochloride (Hcl) has been reported. slower drug
release was observed for blends of HPMC and PVAP compositions as compared to
the single HPMC polymer matrix.
HPMC  With Sodium Alginate
Sodium alginate has also been used Within HPMC matrices to obtain a pH
independent release profile for basic drugs. It has been reported that at low pH (in
gastric environment), sodium alginate precipitates in the hydrated gel layer as
alginic acid. This alginic acid then provides a firm structure to the gel and retards
rate of erosion. Solubility of basic drugs at this pH is high, hence diffusion through
the matrix gel layer predominates as a mechanism of drug release. There are
commercially available ER matrices using the combination of HPMC and sodium
alginate.
Chapter 1 Introduction
Bilayer Floating Tablets Of Metformin Hcl And Sitagliptin Phosphate Page 26
HPMC  With Sodium Carboxy Methyl Cellulose (NaCMC)
Sodium Carboxy Methyl Cellulose (NaCMC) has been reported to have
synergistic hydrogen-bonding interactions with HPMC. Combining HPMC with Na
CMC may result into zero-order release profiles for the drugs Propranolol
Hydrochloride, Metoprolol Tartrate, Oxprenolol Hydrochloride, and Alprenolol
Hydrochloride. However, it was later confirmed that enhancement in viscosity was
not solely responsible for modulating the drug release profile, but that the complex
formation between the anionic polymer and cationic drug also played an important
role. Freely soluble cationic drugs have been reported to be released slower from
combinations of HPMC and Na CMC matrices than when formulated with HPMC
alone, an effect attributed to drug/polymer interaction.
HPMC With Xanthan Gum
Combination of HPMC with xanthan gum has been reported to result in
greater retardation in drug release profile compared to single polymer systems.
Rapid hydration of xanthan gum combined with firm gel strength of HPMC have
been attributed to slower drug release of high-solubility APIs. In this system, the
initial burst release, which is typical of highly soluble drugs, was controlled by rapid
hydration of xanthan gum, whereas subsequent drug release and matrix integrity
were maintained by the firm gel of HPMC.
HPMC & FATTY ACIDS, ALCOHOLS, OR WAXES
Combinations of HPMC and fatty acids, alcohols, or waxes have been
reported with varied degrees of success.49,50 Low-melting lipophilic materials
blended at low concentrations (≤7.5% w/w) with HPMC have shown potential in
achieving the ER of Metformin, a highly solubile active, suggesting the possibility
of niche applications for such matrix blends.49 When used at high concentrations,
because of their low melting points, fatty acids or waxes may enable processing of
HPMC formulations by melt granulation.
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HPMC & NON IONIC HYDROPHILIC POLYMERS
HPMC and poly ethylene oxide [PEO] has been used for modulating drug
release and to prevent the burst release of highly soluble APIs. In addition, the high-
swelling capacity of PEO has been used in HPMC matrices to achieve expanded
swelling, resulting in enhanced gastro-retention of the dosage form. Combination of
HPMC and HPC in the matrix system has been reported to provide retardation in the
drug release profiles compared to single polymer systems. This retardation has been
attributed to a stronger gel layer of the resultant matrix, reducing diffusion and
erosion rate characteristics of the gel layer.
Challenges With Hydrophilic Matrix System
In spite of the presence of numerous products in the marketplace, there are still
some challenges associated with hydrophilic matrix systems,
 Potential burst release with high solubility APIs.
 Size limitations for high dose APIs.
 Potential food effect, and obtaining ph independent release profiles for drugs
that Show ph-dependent solubility.
 Developing new polymeric excipients to overcome these challenges remains
limited due to the regulatory constraints, cost, and establishing safety and
market acceptability
 It was shown that blends of pharmaceutically approved polymeric excipients
have been a powerful strategy to achieve and optimize desired drug release
characteristics and product performance.
1.8 IMMEDIATE RELEASE TABLETS
In many cases, the disintegration time of solid dosage forms is too long to
provide appropriate therapeutic effect. Therefore the disintegration time of the
tablets can be decreased by formulating immediate release tablets. Tablets for
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immediate release often consist of filler, a binder, lubricants and disintegrants. To
improve the disintegration time, so-called disintegrants are used.
The most accepted mechanisms of their action are wicking, swelling,
deformation recovery and particle repulsion. Together, these phenomena create a
disintegrating force within the matrix. In the past, non-modified disintegrants were
used to accelerate disintegration, that is, alginates, starches, ambrelite resins,
cellulosic materials, pectines and others. Today, a fast working superdisintegrants
were chemically modified, typically by crosslinking the organic chains of a
polymeric molecules.
Superdisintegrants
Three classes of superdisintegrants are commonly used: modified cellulose
(croscarmellose sodium - Ac-Di-Sol®, Vivasol®), crosslinked polyvinyl-
lpyrrolidone (Polyplasdone® XL-10) and modified starch (Sodium Starch Glycolate
– Primojel®, Explotab®).
Mechanism Of Superdisintegrants
The tablet breaks to primary particles by one or more of the mechanisms
listed below.
1. Because of Heat of Wetting (Air Expansion):
When disintegrants with exothermic properties gets wetted, localized stress
is generated due to capillary air expansion, which helps in disintegration of tablet.
This explanation, however, is limited to only a few types of disintegrants and can
not describe the action of most modern disintegrating agents.
2. Swelling: Perhaps the most widely accepted general mechanism of action for
tablet disintegration is swelling. Tablets with high porosity show poor disintegration
due to lack of adequate swelling force. On the other hand, sufficient swelling force
is exerted in the tablet with low porosity. It is worthwhile to note that if the packing
fraction is very high, fluid is unable to penetrate in the tablet and disintegration is
again slows down.
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3. Porosity and Capillary Action (Wicking):
Disintegration by capillary action is always the first step. When we put the
tablet into suitable aqueous medium, the medium penetrates into the tablet and
replaces the air adsorbed on the particles, which weakens the intermolecular bond
and breaks the tablet into fine particles. Water uptake by tablet depends upon
hydrophilicity of the drug/excipient and on tableting conditions. For these types of
disintegrants maintenance of porous structure and low interfacial tension towards
aqueous fluid is necessary which helps in disintegration by creating a hydrophilic
network around the drug particles.
4. Due To Disintegrating Particle/Particle Repulsive Forces:
Another mechanism of disintegration attempts to explain the swelling of
tablet made with ‘non-swellable’ disintegrants. Guyot-Hermann has proposed a
particle repulsion theory based on the observation that non swelling particle also
cause disintegration of tablets. The electric repulsive forces between particles are the
mechanism of disintegration and water is required for it. Researchers found that
repulsion is secondary to wicking.
5. Due To Deformation:
During tablet compression, disintegranted particles get deformed and these
deformed particles get into their normal structure when they come in contact with
aqueous media or water. Occasionally, the swelling capacity of starch was improved
when granules were extensively deformed during compression. This increase in size
of the deformed particles produces a break up of the tablet. This may be a
mechanism of starch and has only recently begun to be studied.
6. Due To Release of Gases:
Carbon dioxide released within tablets on wetting due to interaction between
bicarbonate and carbonate with citric acid or tartaric acid. The tablet disintegrates
due to generation of pressure within the tablet. This effervescent mixture is used
when pharmacist needs to formulate very rapidly dissolving tablets or fast
disintegrating tablet. As these disintegrants are highly sensitive to small changes in
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humidity level and temperature, strict control of environment is required during
manufacturing of the tablets. The effervescent blend is either added immediately
prior to compression or can be added in to two separate fraction of formulation.
Table showing properties of important superdisintegrants used in the study
S no Superdisintegrant properties
1 Cros carmellose
sodium
High swelling capacity, effective at low concentration
(0.5-2.0%), can be used up to 5%
2 Crospovidone Completely insoluble in water. Rapidly disperses and
swells in water, but does not gel even after prolonged
exposure. Greatest rate of swelling compared to other
disintegrants.
Greater surface area to volume ratio than other
disintegrants. Effective concentration (1-3%). Available in
micronized grades if needed for improving state of
dispersion in the powder blend.
3 Sodium starch
glycolate
Absorbs water rapidly, resulting in swelling up to 6%.
High concentration causes gelling and loss of
disintegration
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Table Showing Various Superdisintegrants and Their Applications.
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2.  LITERATURE REVIEW
Fiona Palmer et al1., Investigated the effect of Hypromellose on  Direct Compression
of Metformin HCl 500mg to form an  Extended Release Formulation Extended release
(ER) formulation of metformin hydrochloride (HCl) presents the formulator with
significant challenges due to its poor inherent compressibility, high dose and high water
solubility. This study investigates the possibility for development of a direct
compression ER matrix tablet using hypromellose by taking different ratios of
Methocel K4M CR, Methocel K100M CR, 30%w/w inclusion of the controlled release
polymer in the formula resulted in drug release profile similar to the Glucophage XR
(500mg) tablet.
Basawaraj S. Patil et al2., Prepared Fast dissolving tablets (FDT) of Granisetron
hydrochloride  by direct compression method by incorporating superdisintegrants
croscarmellose sodium and crospovidone in different concentrations (2.5, 5, 7.5 and 10
mg). The formulation GCS4 containing croscarmellose sodium showed superior in
vitro dispersion time and drug release, as compared to other formulations. GCS4 tablet
showed good dissolution efficiency and rapid dissolution. The 50% and 90% of drug
release of tablet GCS4, was found within 0.45 and 2.59 min.
Praveen Nasa et al3., Formulated and characterized a floating drug delivery system,
using Methocel K100M and E50.for  Metformin  hydrochloride by wet granulation
method. The two grades were evaluated for their gel forming properties It was
concluded that the formulation F5 (containing 160 mg of Methocel K100M and 40 mg
of Methocel E50) was the optimum formulation amongst all the test batches. It may also
be concluded from the investigation that a combination of Methocel K100M and
Methocel E50 in the ratio of 4:1 may be satisfactorily employed in the formulation of a
floating drug delivery system.
Durga Prasad Pattanayak et al4., The present research work was an attempt to
design a formulation to improve the oral therapeutic efficacy with optimal control of
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plasma drug level which contains two antidiabetic drugs i.e Metformin HCl and
Glimepiride. a common analytical method for quantitative combined drug estimation
was employed and evaluated.  Two different matrix formulations were developed, one
matrix layer with hydrophilic swellable polymer HPMC and another with hydrophobic
polymer PEO as carriers for sustained drug delivery from matrices and were evaluated.
Lian-Dong Hu et al5., In this study, metformin hydrochloride (MH) sustained-release
pellets were successfully prepared by centrifugal granulation. Seed cores preparation,
drug layering, talc modification and coating of polymeric suspensions were carried out
in a centrifugal granulator. After using Eudragit NE30D alone and a blend of Eudragit_
L30D-55/Eudragit_ NE30D (1:20)for coating, three kinds of sustained-release pellets
with different formulations were obtained. The in vivo bioavailability showed varying
sustained-release characteristics for the coated pellets when compared with IR MH
tablets.
Sachin S. Kale et al6., Mentioned that Bilayer tablet is new era for the successful
development of controlled release formulation along with various features to provide a
way of successful drug delivery system.. Bi-layer tablet is suitable for sequential release
of two drugs in combination, separate two incompatible substances and also for
sustained release tablet in which one Layer is immediate release as initial dose and
second layer is maintenance dose. In the case of bilayered tablets drug release can be
rendered almost unidirectional if the drug can be incorporated in the upper nonadhesive
layer its delivery occurs into the whole oral cavity.
Sandip B. Tiwari et al 7., In the post Hatch-Waxman Act 1984 era, developing an
extended release (ER) formulation of a new chemical entity with extended patent life
has become very crucial to innovator companies.. Hydrophilic matrix systems have
been widely studied and accepted as an ER approach for oral drug delivery, It was
shown that blends of pharmaceutically approved polymeric excipients have been a
powerful strategy to achieve and optimize desired drug release characteristics and
product performance. Combinations of HPMC with ionic and nonionic polymers have
Chapter  2 Literature Review
Bilayer Floating Tablets Of Metformin Hcl And Sitagliptin Phosphate Page 34
been used in hydrophilic matrices to modulate the release profile and overcome some or
all of the challenges observed with hydrophilic matrices.
Suvakanta dash et al 8., In this paper they reviewed the mathematical models used to
determine the kinetics of drug release from drug delivery systems. The quantitative
analysis of the values obtained in dissolution/release rates is easier when mathematical
formulae are used to describe the process. The mathematical modeling can ultimately
help to optimize the design of a therapeutic device to yield information on the efficacy
of various release models.
Ganesh Rajput et al 9., The present investigation is aimed to formulate floating tablets
of metformin hydrochloride using an effervescent approach for gastroretentive drug
delivery system. Floating tablets were prepared using directly compressible method
using polymers HPMC K 100M and HPMC K 4M for their gel-forming properties. It
was concluded that polymer viscosity had major influence on drug release from
hydrophilic matrix tablets as well as on floating lag time. The different ratios of HPMC
K 4M and HPMC K 100M were evaluated to achieve apparent viscosity to 66633 cps.
The optimized batch showed the highest f2=82 value, it contained 37.34mg of HPMC K
4M and 212.66mg of HPMC K100M.
M. M. Varma et al 10., Sustained release gastroretentive dosage forms enable
prolonged and continuous input of the drug to the upper parts of gastrointestinal tract.
Gastroretentive floating drug delivery systems (GFDDS) of metformin hydrochloride,
an antidiabetic drug with an oral bioavailability only 50%(because of its poor
absorption from lower gastrointestinal tract) have been designed and evaluated.
Hydroxy propyl methyl cellulose(HPMC K4M) and carbopol 934P were used as
polymers and sodium bicarbonate as gas generating agent to reduce floating lag
time.The in vitro drug release followed first order kinetics and drug release was found
to be diffusion controlled.
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K. Gupta et al 11., A simple, precise and highly selective analytical method was
developed for simultaneous estimation of Metformin HCl and Sitagliptin in tablet
formulation. Estimation was carried out by multi-component mode of analysis at
selected wavelength of 232 nm and 267 nm for Metformin HCl and Sitagliptin
respectively in distilled water. The method was found to be linear in the range of 1-40
μg/ml and accuracy of the method was confirmed by recovery studies of tablet dosages
forms and was found to be 99.35% and 98.33% for Metformin HCl and Sitagliptin
respectively. % concentration of Metformin HCl and Sitagliptin in marketed
formulation was found to be 98.26% ± 0.29 and 97.35% ± 1.38 respectively. The values
of precision and robustness lie within acceptable limit.
N.N.Rajendran et al 12., The present study was to establish Bi‐layer tablets containing
Metformin HCl as sustained release and Pioglitazone HCl as immediate release layer.
immediate release layer were prepared by direct compression method using
superdisintegrants such as sodium starch glycolate and crosscarmellose sodium. All the
values were found to be within limit. The result showed that combinations of polymers
namely HPMC K100M and HPMC K4M in sustained layer can control the release of
drug. The in vitro release profiles follows Higuchi’s equation as the plots showed high
linearity (R2 >0.988) and diffusion was the mechanism of drug release. The
formulations (P6M7) having immediate release layer produces immediate effect within
54 second followed by sustained release (97.35%) at 8 hrs and it comparable with
innovator.
Shubhangi B. Bagde et al 13., In the present investigation an attempt was made to
reduce the dose frequency, to prevent nocturnal heart attack and to improve the patient
compliance by developing a Bilayer tablet having extended release (ER) layer of
Metoprolol succinate and immediate release(IR) layer of Ramipril.
Hydroxylpropylmethylcellulose K100M and Sodium Carboxymethylcellulose was used
for extended release of Metoprolol succinate. Among the Ten formulations, F
10 showed
compliance with US pharmacopoeial standards, extend the release of drug for 20 hours
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with 99.6% drug release and subjected to stability studies for 1 month at 40 0C/75%
RH.
Himansu Bhusan Samal et al 14., The investigation was concerned with design and
characterization of oral Sustained release matrix tablets of Zidovudine (AZT) in order to
improve efficacy and better patient compliance. Matrix tablets were prepared by Wet
granulation method using various proportions of hydrophilic polymers like Sodium
CMC, HPMC, Eudragit‐L155, & Xanthan gum along or in combination with
hydrophobic polymer ethyl cellulose. From the above study it was concluded that
presence of sodium CMC gives zero‐order release kinetics and the linearity ranges from
0.990 to 0.996. It has also good drug entrapment efficiency ranges from 96 to 106% of
drug. Formulation containing sodium CMC with Xanthan gum and EC gives sustained
release of drug more than 12hrs.
Subas C. Dinda et al 15., The objective of the present study is to formulate a fixed dose
combined drug formulation of valsartan (VAL) as an immediate release layer and
metformin HCl (MHCl) as a sustained release form using bilayer tablet technology,
which enables biphasic drug release for once daily dosing to get a better therapeutic
efficacy. The immediate release layer was prepared using super disintegrant
crospovidone and extended release layer using hydroxypropylmethylcellulose (HPMC
K100M), sodium carboxy methyl cellulose and povidone K90.
Honey Goel et al 16., Orally disintegrating systems have carved a niche amongst the
oral drug delivery systems due to the highest component of compliance they enjoy in
patients especially the geriatrics and pediatrics. In addition, patients suffering from
dysphagia, motion sickness, repeated emesis and mental disorders prefer these
medications because they cannot swallow large quantity of water. Further, drugs
exhibiting satisfactory absorption from the oral mucosa or intended for immediate
pharmacological action can be advantageously formulated in these dosage forms. A
variety of dosage forms like tablets, films, wafers, chewing gums, microparticles,
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nanoparticles etc. have been developed for enhancing the performance attributes in the
orally disintegrating systems
Bala Sekaran.C et al 17., A simple, sensitive and reproducible spectrophotometric
method was developed for the determination of sitagliptin phosphate in bulk and in
pharmaceutical formulations. The proposed method is based on condensation of the
primary amino group of sitagliptin phosphate with acetyl acetone and formaldehyde
producing a yellow colored product, which is measured spectrophotometrically at
430nm. Beer’s law is obeyed over a concentration range of 5‐25 μg/ml. No interference
was observed in the presence of common pharmaceutical excipients. The validity of the
method was tested by analyzing sitagliptin phosphate in its pharmaceutical preparations.
S.B Shirsand et al 18., In the present study, novel co-processed superdisintegrants were
developed by solvent evaporation method using crospovidone and croscarmellose
sodium in the different ratios (1:1, 1:2 & 1:3) for use in the fast dissolving tablet
formulations. Fast dissolving tablets of metoclopramide hydrochloride were prepared
using the above co-processed superdisintegrants. Among the designed formulations, the
formulation (CP1) containing 4% w/w of co-processed superdisintegrant (1:1 mixture of
crospovidone and croscarmellose sodium) emerged as the overall best formulation
(t50% 2.4 min) based on drug release characteristics in pH 6.8 phosphate buffer
compared to commercial conventional tablet formulation (t50% 6 min).
Jonathan K Reynolds19., JanumetTM, a fixed dose combination of
sitagliptin/metformin HCL manufactured by Merck Pharmaceuticals, has received US
Food and Drug Administration approval for treatment of patients with type 2 diabetes,
that are inadequately controlled, either by sitagliptin or metformin alone or together in
free-dose combination form. Sitagliptin, an inhibitor of the enzyme DDP-4, assists
patients with type 2 diabetes mellitus to achieve glycemic control. It has been shown to
be safe and effective at 100 mg daily doses. The effect of giving sitagliptin in
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combination with metformin is thought to have a complimentary and possibly additive
effect on glycemic control.
Eytan A. Klausner et al 20., These GRDFs are easily swallowed and reach a
significantly larger size in the stomach due to swelling or unfolding processes that
prolong their gastric retention time (GRT). After drug release, their dimensions are
minimized with subsequent evacuation from the stomach. Gastroretentivity is enhanced
by the combination of substantial dimensions with high rigidity of the dosage form to
withstand the peristalsis and mechanical contractility of the stomach.. Narrow
absorption window drugs compounded in such systems have improved in vivo
absorption properties. The current review deals with expandable GRDFs reported in
articles and patents, and describes the physiological basis of their design.
Madhusudan Rao Yamsani et al 21., The purpose of writing this review on floating
drug delivery systems (FDDS) was to compile the recent literature with special focus on
the principal mechanism of floatation to achieve gastric retention. One of the most
feasible approaches for achieving a prolonged and predictable dug delivery profiles in
the gastrointestinal tract is to control the gastric residence time, using gastroretentive
dosage forms that will provide us with new and important therapeutic options. From the
formulation and technological point of view, the floating drug delivery system is
considerably easy and logical approach.
A Ramachandran et al 22., The prevalence of diabetes is rising all over the world due
to population growth, aging, urbanisation and an increase of obesity and physical
inactivity. The International Diabetes Federation (IDF) estimates the total number of
people in India with diabetes to be around 50.8 million in 2010, rising to 87.0 million
by 2030. The primary goal in the management of diabetes mellitus is the attainment of
near-normal glycaemia. Glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl
peptidase-4 (DPP-4) are novel agents that show promising results. Exenatide is the first
in the incretin mimetic class and liraglutide is a once-daily human GLP-1 analogue.
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3. SCOPE AND OBJECTIVE
3.1 Scope of the work
Diabetes is one of the most prevailing and advancing diseases in the world
having affected 6.6% of the world population 22. Metformin hydrochloride is the most
widely used Oral Anti Diabetic drug in the world. Metfromin shows high aqueous
solubility and low cell membrane permeability. The usual dosage for Metformin is 250–
500 mg 3-4 times daily, up to a maximal of 2.5 g/day. The absolute bioavailability of
Metformin hydrochloride is 50–60% and is having short biological half-life of 6.2 hrs.
The use of Metformin therapy has the high incidence of gastrointestinal side
effects. Frequent dosing schedule leading to high GI side effects and high daily dose
makes its use unsuccessful, thus it is reasonable to formulate sustained release
Metformin tablets to prolong its duration of action and to reduce total dose of drug
administered as well as the incidence of adverse side effects, thus improving the patient
compliance.
A conventional oral sustained release formulation release most of the drug
content at colon. Since Metformin has absorption window in stomach & upper part of
GIT up to intestine, there is a need to develop gastro retentive sustained release
formulation which, In contrast to conventional extended-release Metformin tablets
reported in the literature gives extended plasma concentration time profiles, increased
bioavailability with lower C max and greater T max 10.
The combination of a DPP-4 Inhibitor with Metformin allows a broad and
complementary spectrum of anti diabetic actions. This combination does not increase
the risk of hypoglycemia, do not promote weight gain, and do not cause adverse effect
caused by various other oral anti diabetic combinations. Both the drugs have a
complimentary and possibly additive effect on glycemic control and reduced
glycosylated haemoglobin (HbA(1c)) levels 22.
Bi-layer tablet is suitable for sequential release of two drugs in combination,
separating two incompatible substances. Typically an immediate release granulate is
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first compressed followed by the addition of a controlled release element which is
compressed onto .the .initial tablet, this gives. the characteristic. Bi-layer. effect to the
final. dosage .form. In the case of bi-layered tablets drug release can be rendered
almost unidirectional 6.
HPMC is the mostly used nonionic water soluble polymer showing  pH
independent and desired drug release profiles for a wide range of drugs, provide robust
formulation, global availability, cost-effective manufacture. HPMC is typically  used as
the primary polymer, and other approved polymer(s) have been added to enhance
functionality and as a tool to modulate the drug release profile 7.
Sodium Carboxy Methyl Cellulose (Na CMC) has been reported to have
synergistic hydrogen-bonding interactions with HPMC 7. Freely soluble cationic drugs
have been reported to be released slower from combinations of HPMC and Na CMC
matrices than when formulated with HPMC alone.
Superdisintegrants are the agents that promote fast disintegration of the tablets
by increasing water penetration and dispersion of the matrix 16. Here, in this study cross
povidone, croscarmellose sodium, sodium starch glycolate were used a
superdisintegrants and were evaluated for their effect on dissolution and disintegration
of Sitagliptin layer. Fixed dose combinations (or) combination therapy (Two or more
active ingredients in one dosage form)  offer several advantages such as lower cost,
improved efficacy, better compliance as number of doses/ pills per day decreases, and
fewer side effects. Thus currently focus is shifting fast  to fixed dose combinations in
the form of bi layer (or) multi layer dosage forms to treat diseases like Diabetes,
Hypertension, Tuberculosis, HIV etc
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3.2 Objective of the Work
The main objective of present study is to develop a dosage form which provides
fixed dose combination therapy for the treatment of NIDDM. Since the combination of
Metformin Hcl and Sitagliptin shows complimentary and possibly additive effect on
glycemic control and reduced glycosylated haemoglobin (HbA(1c)) levels with no weight gain
and reduced side effects.
The objectives of the present study are:
1. To improve the Bioavailability of Metformin by formulating as floating SR
layer.
2. To reduce the dose, dosage frequency, dose related side effects and number of
tablets per day by formulating Metformin and Sitagliptin as Bilayer tablets.
3. To study the effect of different concentrations of hydrophilic polymers like
HPMC K100 M and Sodium CMC on release of Metformin .
4. To study the effect of different Superdisintegrants on drug release pattern from
the immediate  release layer.
5. To study the effect of different concentrations of sodium bi-carbonate on
floating behavior.
6. To investigate the mechanism of release of Metformin from SR layer.
.
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4.2 DRUG PROFILE
METFORMIN   HYDROCHLORIDE 52, 54
Structure
Chemical Name : 1-carbamimidamido-N,N-dimethylmethanimidamide
Empirical Formula : C4H11N5.HCl
Molecular Weight : 165.62
Melting Point : 222 to 226 oC
Category : Hypoglycemic agent
Dose : 0.5 to 3 g daily, in divided doses 35
PKa : 12.4
pH : pH of 1% aqueous solution of drugs is 6.68
Description : White, crystalline powder, hygroscopic which is odor
less and    has a bitter taste.
Appearance, odor and Color : Metformin HCl is a white, hygroscopic powder,
Solubility: Freely soluble in water, slightly soluble in ethanol (95%), practically
insoluble in acetone, chloroform, dichloromethane and ether.
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Pharmacokinetics:
Absorption: It is a BCS class III (highly soluble- poorly permeable) drug. The
absolute bioavailability under fasting conditions is approximately 50-60%.  It is
absorbed mainly from the upper part of small intestine.  There is a lack of dose
proportionality with increasing doses, which is due to decreased absorption rather
than an alteration in elimination. Food decreases and slightly delays the absorption
of metformin.
Distribution: The apparent volume of distribution (Vd) of metformin is 654 liters.
Metformin is negligibly bound to plasma proteins, in contrast to sulfonylureas,
which are more than 90% protein bound. At usual clinical doses and dosing
schedules, steady state plasma concentrations of metformin reached within 24-48
hours and are generally less than 1 µg/ml.
Metabolism And Elimination: Metformin is excreted unchanged in the urine and
neither undergo hepatic metabolism, nor biliary excretion. Renal clearance is
approximately 3.5 times greater than creatinine clearance. Following oral
administration, approximately 90% of the absorbed drug is eliminated via the renal
route within the first 24 hours, with a plasma elimination half-life of approximately
3 hours. Duration of action is 8-12 hours.
Dosage and Administration:
The usual effective dosage of metformin hydrochloride is 1500- 2550
mg/day given in divided doses. It is commercially available in tablets of 500 mg or
850 mg immediate release and 500 mg and 1000 mg extended release tablets.
There is no fixed regimen for the management of hyperglycemia in patients
with type II diabetes. Dosage must be individualized on the basis of both
effectiveness and tolerance, while not exceeding the maximum recommended daily
dose. The maximum recommended daily dose of extended release tablet in adult is
2500 mg.
Adverse Effects:
Approximately 30% of patients may have gastrointestinal adverse effects,
such as diarrhoea, nausea, epigastric discomfort, and anorexia. Gastrointestinal side
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effects are commonly dose related; gradually increasing the dosage.  Taking doses
with food or temporarily reducing the dosage may help avoid these reactions. The
most worrisome adverse effect of metformin is lactic acidosis
SITAGLIPTIN  PHOSPHATE 53:
Structure:
Chemical Name : 4-Oxo-4-(3-(trifluoromethyl)-5,6dihydro(1,2,4)triazolo[4,3
a]pyrazin-7(8H)-yl)-1-(2,4,5-trifluorophenyl)butan-2-
amine phosphate
Empirical Formula : C16H15F6N5O.H3PO4
Molecular Weight : 505.31
Melting Point : 198 - 202 C
Category : Hypoglycemic agent DPP-4 inhibitor.
Dose : 25 to 100 mg daily, in divided doses or once daily.
PKa : 12.4
pH : pH of 1% aqueous solution of drugs is 6.68
Description : white to off-white crystalline powder
Solubility: Freely soluble in water, slightly soluble in ethanol (95%), practically
insoluble in acetone, chloroform, dichloromethane and ether.
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Pharmacokinetics:
Absorption: It is a BCS class I (highly soluble- highly permeable) drug. Rapidly
absorbed following oral administration, with an absolute bioavailability of 87%
Distribution: The apparent volume of distribution (Vd) of metformin is 198 L
[healthy subjects]. The fraction of sitagliptin reversibly bound to plasma proteins is
low (38%).
Metabolism And Elimination: Sitagliptin does not undergo extensive metabolism.
In vitro studies indicate that the primary enzyme responsible for the limited
metabolism of Sitagliptin was CYP3A4 (oxidation), with contribution from
CYP2C8. Approximately 79% of Sitagliptin is excreted unchanged in the urine with
metabolism being a minor pathway of elimination. Elimination of Sitagliptin occurs
primarily via renal excretion and involves active tubular secretion. Half life is 12.4
hours.
Mechanism of Action:
Sitagliptin is a highly selective DPP-4 inhibitor, thereby increasing the concentration
and prolonging the action of incretin hormones like glucagon-like peptide-1 (GLP-1)
and glucose-dependent insulinotropic polypeptide (GIP), which are generally
inactivated by the enzyme, DPP-4.
.
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4.2 EXCIPIENT PROFILE
HYDROXY PROPYL METHYL CELLULOSE 46:
Non-Proprietary Names:
BP: Hypromellose          JP: Hydroxypropylmethylcellulose
PhEur: Hypromellosum  USP: Hypromellose
Synonyms: Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC;
Methocel; methylcellulose propylene glycol ether; methyl hydroxypropylcellulose;
Metolose; Tylopur.
Chemical Name : Cellulose hydroxypropyl methyl ether [9004-65-3]
Empirical Formula: C8H15O6 – (C10H18O6)n – C8H15O5 Molecular weight is
approximately 10 000–1 500 000.
Description:
Hypromellose is an odorless and tasteless, white or creamywhite fibrous or granular
powder
Structural Formula:
Functional Category:
Coating agent, film-former, rate-controlling polymer for sustained release,
stabilizing agent, suspending agent, tablet binder, viscosity-increasing agent.
Density: 0.25 – 0.70 g/cm3
Solubility:
Soluble in cold water forming a viscous colloidal solution. practically insoluble in
chloroform, ethanol (95%), and ether, but soluble in mixtures of ethanol and
dichloromethane, mixtures of methanol and dichloromethane, and mixtures of water
and alcohol.
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Melting point: Browns at 190–2008C. Chars at 225–2308C. Glass transition
temperature is 170–1808C.
Moisture content:
Hypromellose absorbs moisture from the atmosphere. The amount of water absorbed
depends upon the initial moisture content and the temperature and relative humidity
of the surrounding air.
Viscosity:
A wide range of viscosity types are commercially available. Aqueous solutions are
most commonly prepared, although hypromellose may also be dissolved in aqueous
alcohols such as ethanol and propan- 2-ol provided the alcohol content is less than
50% w/w.
Safety:
It is widely used in many oral and topical pharmaceutical formulations. It is
generally regarded as a non-toxic and non-irritant material, although excessive
consumption may have laxative effect.
Pharmaceutical Applications:
 Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical
formulations
 In oral products, hypromellose is primarily used as a tablet binder, in film-
coating, and as a matrix for use in extended-release tablet formulations.
Concentrations between 2% and 5% w/w may be used as a binder in either
wet- or dry-granulation processes. High-viscosity grades may be used to
retard the release of drugs from a matrix at levels of 10–80% w/w in tablets
and capsules.
 Depending upon the viscosity grade, concentrations of 2–20% w/w are
used for film-forming solutions to film-coat tablets. Lower-viscosity grades
are used in aqueous film-coating solutions, while higher-viscosity grades
are used with organic solvents.
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SODIUM CARBOXY METHYL CELLULOSE46
Nonproprietary Names:
BP: Carmellose sodium JP: Carmellose sodium
PhEur: Carmellosum natricum USP: Carboxymethylcellulose sodium
Synonyms:
Akucell; Aquasorb; Blanose; cellulose gum; CMC sodium; E466; Finnfix; Nymcel;
SCMC; sodium carboxymethylcellulose; sodium cellulose glycolate; sodium CMC;
Tylose CB.
Chemical Name : Cellulose, carboxymethyl ether, sodium salt [9004-32-4]
Empirical Formula and Molecular Weight:
The USP 28 describes carboxy methyl cellulose sodium as the sodium salt of poly
carboxy methyl ether of cellulose. Typical molecular weight is 90 000–700 000.
Structural Formula:
Functional Category
Coating agent, stabilizing agent, suspending agent, tablet and capsule disintegrant,
tablet binder,  viscosity-increasing agent, water-absorbing agent.
S No Uses of Carboxy Methyl Cellulose
Sodium.
Use Concentration (%)
1 Emulsifying agent 0.25- 1.0
2 Gel-forming agent 3.0- 6.0
3 Injections 0.05 – 0.75
4 Oral solutions 0.1 – 1.0
5 Tablet binder 1.0 – 6.0
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Description:
Carboxymethylcellulose sodium occurs as a white to almost white, odorless,
granular powder.
Moisture Content: `
Typically contains less than 10% water. However, carboxymethylcellulose
sodium is hygroscopic and absorbs significant amounts of water at temperatures up
to 378C at relative humidities of about 80%.
Solubility:
Practically insoluble in acetone, ethanol (95%), ether, and toluene. Easily
dispersed in water at all temperatures, forming clear, colloidal solutions. The
aqueous solubility varies with the degree of substitution (DS). various grades of
Carboxy Methyl Cellulose Sodium are commercially available that have differing
aqueous
Viscosities;
Aqueous 1% w/v solutions with viscosities of 5–13 000 mPa s (5–13 000 cP) may
be obtained.
Applications in Pharmaceutical Formulation or Technology
 Carboxymethylcellulose sodium is widely used in oral and topical
pharmaceutical formulations, primarily for its viscosityincreasing properties.
 Carboxymethylcellulose sodium may also be used as a tablet binder and
disintegrant,( 3–6) and to stabilize emulsions. Higher concentrations, usually
3–6%, of the medium viscosity grade are used to produce gels that can be
used as the base for applications and pastes;
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CROSPOVIDONE
Nonproprietary Names:
BP: Crospovidon, PhEur: Crospovidonum, USPNF: Crospovidone
Synonyms
Crosslinked povidone, E1202, Kollidon CL, Kollidon CL-M, Polyplasdone XL,
Polyplasdone XL-10, poly vinyl poly pyrrolidone, PVPP, 1-vinyl-2-pyrrolidinone
homopolymer.
Chemical Name: 1-Ethenyl-2-pyrrolidinone homopolymer [9003-39-8]
Empirical Formula and Molecular Weight : (C6H9NO)n >1 000 000
Functional Category : Tablet disintegrant.
Description
Crospovidone is a white to creamy-white, finely divided, freeflowing, practically
tasteless, odorless or nearly odorless, hygroscopic powder.
Specific Surface Areas for commercial grades of Crospovidone
Applications in Pharmaceutical Formulation
 Crospovidone is a water-insoluble tablet disintegrant and dissolution agent
used at 2–5% concentration in tablets prepared by direct-compression or wet-
and dry granulation methods. It rapidly exhibits high capillary activity and
pronounced hydration capacity, with little tendency to form gels.
 Larger particles provide a faster disintegration than smaller particles.
 Crospovidone can also be used as a solubility enhancer. With the technique
of co-evaporation, crospovidone can be used to enhance the solubility of
poorly soluble drugs.
S no Commercial grade Surface area (m2/g)
1 Kollidon CL 1.0
2 Kollidon CL-M 3.0- 6.0
3 Polyplasdone XL 0.6 – 0.8
4 Polyplasdone XL 1.2 – 1.4
Chapter 4 Drug And Excipient Profile
Bilayer Floating Tablets Of Metformin Hcl And Sitagliptin Phosphate Page 51
CROSCARMELLOSE  SODIUM 46
Nonproprietary Names
BP: Croscarmellose sodium, PhEur: Carmellosum natricum conexum
USPNF: Croscarmellose sodium
Synonyms
Ac-Di-Sol; crosslinked carboxymethylcellulose sodium, Explocel, modified
cellulose gum, Nymcel ZSX, Pharmacel XL, Primellose, Solutab, Vivasol.
Chemical Name and CAS: Cellulose, carboxymethyl ether, sodium salt,
crosslinked [74811-65-7]
Empirical Formula and Molecular Weight
Croscarmellose sodium is a Crosslinked polymer of carboxy Methyl Cellulose
sodium.
Functional Category: Tablet and capsule disintegrant.
Description
Croscarmellose sodium occurs as an odorless, white or grayishwhite Powder
Particle size Distribution
Ac-Di-Sol: Not more than 2% retained on a #200 (73.7 mm) mesh and not more
than 10% retained on a #325 (44.5 mm) mesh.
Pharmacel XL: More than 90% less than 45 mm, and more than 98% less than 100
mm in size.
Solubility: Insoluble in water, although croscarmellose sodium rapidly swells to 4–8
times its original volume on contact with water. Practically insoluble in acetone,
ethanol and toluene.
Applications
 Croscarmellose sodium is used in oral pharmaceutical formulations as a
disintegrant for capsules tablets, and granules.
 When used in wet granulations, the croscarmellose sodium should be added
in both the wet and dry stages of the process (intra- and extragranularly) so
that the wicking and swelling ability of the disintegrant is best utilized.
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 Croscarmellose sodium at concentrations up to 5% w/w may be used as a
tablet disintegrant, although normally 2% w/w is used in tablets prepared by
direct compression and 3% w/w in tablets prepared by a wet-granulation
process.
Uses of Croscarmellose Sodium
S no Use Concentration (%)
1 Disintegrant in capsules 10–25
2 Disintegrant in tablets 0.5–5.0
SODIUM  STARCH  GLYCOLLATE46
Nonproprietary Names
BP: Sodium starch glycollate, PhEur:Carboxymethylamylum natricum
USPNF: Sodium starch glycolate
Synonyms
Carboxymethyl starch, sodium salt; Explosol; Explotab; Glycolys; Primojel; starch
carboxymethyl ether, sodium salt; Tablo; Vivastar P.
Chemical Name and CAS Number: Sodium carboxymethyl starch [9063-38-1]
Structural Formula:
Functional Category: Tablet and capsule disintegrant.
Applications in Pharmaceutical Formulation:
 Sodium starch glycolate is widely used in oral pharmaceuticals as a
disintegrant in capsule and tablet formulations It is commonly used in tablets
prepared by either direct compression or wet-granulation processes.
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 Usual concentration employed in a formulation is between 2% and 8%, with
the optimum concentration about 4%, although in many cases 2% is
sufficient.
 Disintegration occurs by rapid uptake of water followed by rapid and
enormous Swelling Although the effectiveness of many disintegrants is
affectedby the presence of hydrophobic excipients such as lubricants, the
disintegrant efficiency of sodium starch glycolate is unimpaired.
Description
Sodium starch glycolate is a white to off-white, odorless, tasteless, free-flowing
powder. The PhEur 2005 states that it consists of oval or spherical granules, 30–100
mm in diameter, with some less-spherical granules ranging from 10–35 mm in
diameter.
Particle size distribution: 100% of particles less than 106 mm in size. Average
particle size is 35–55 mm for Explotab.
Solubility: sparingly soluble in ethanol (95%); practically insoluble in water. At a
concentration of 2% w/v sodium starch glycolate disperses in cold water and settles
in the form of a highly hydrated layer.
Swelling capacity: In water, sodium starch glycolate swells to up to 300 times its
volume.
PRE  GELATINISED  STARCH46
Non-proprietary Name
BP: Pregelatinised starch, PhEur: Amylum pregelificatum
USPNF: Pregelatinized starch
Synonyms: Compressible starch, Instastarch, Lycatab C, Lycatab PGS, Merigel,
National 78-1551, Pharma-Gel, Prejel, Sepistab ST 200, Spress B820, Starch 1500
G; Tablitz, Unipure LD, Unipure WG220.
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Chemical Name and CAS Number: Pregelatinized starch [9005-25-8]
Empirical Formula and Molecular Weight: (C6H10O5)n where n = 300–1000
Functional Category: Tablet and capsule diluent; tablet and capsule disintegrant;
tablet binder.
Applications in Pharmaceutical Formulation
 Pregelatinized starch is a modified starch used in oral capsule and tablet
formulations as a binder, diluent,(1,2) and disintegrant.
 In comparison to starch, grades of pregelatinized starch may be produced
with enhanced flow and compression characteristics such that the
pregelatinized material may be used as a tablet binder in dry-compression or
direct compression processes.
Uses of Pre gelatinized Starch
S no Use Use concentration (%)
1 Diluent (hard gelatin capsules) 5–75
2 Tablet binder (direct compression) 5–20
3 Tablet binder (wet granulation) 5–10
4 Tablet disintegrant 5–10
Description
Pregelatinized starch occurs as a moderately coarse to fine, white to off-white
colored powder. It is odorless and has a slight characteristic taste
Moisture content: pregelatinized maize starch is hygroscopic.
Particle size distribution: 30–150 mm, median diameter 52 mm. For partially
pregelatinized starch, greater than 90% through a US #100 mesh (149 mm); and less
than 0.5% retained on a US #40 mesh (420 mm).
Solubility: practically insoluble in organic solvents. Slightly soluble to soluble in
cold water, depending upon the degree of pregelatinization. Pastes can be prepared
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by sifting the pregelatinized starch into stirred, cold water. Cold-watersoluble matter
for partially pregelatinized starch is 10–20%.
Viscosity (dynamic): 8–10 mPa s (8–10 cP) for a 2% w/v aqueous dispersion
at258C.
SODIUM BICARBONATE46
Non-proprietary names: BP/EP: sodium bicarbonate
Synonym: Baking soda, e-500, and monosodium carbonate.
Chemical name: carbonic acid, monosodium salt, monosodium carbonate.
Empirical formula: NaHCO3
Molecular weight: 84.01
Category: alkalizing agent, therapeutic agent.
Description: it is an odorless, white crystalline powder with slight alkaline taste.
Acidity/ alkalinity: pH 8.3 for freshly prepared 0.1m aqueous solution at 250c.
Density: 2.159 g/cm3
Solubility: Soluble in water, practically insoluble in ethanol.
Stability and storage: Sodium bicarbonate is stable in dry air but slowly
decomposes in Moist air and should therefore be stored in well-closed container in a
cool dry place.
Safety: Orally ingested sodium bicarbonate neutralizes gastric acid with the
evolution of carbon dioxide and may cause stomach cramps and flatulence.
Applications:
1. Employed as a source of carbon dioxide in effervescent tablets
and granules.
2. Also used to buffer the drug molecules that are weak acids.
3. Used in solutions as buffering agent.
4. Also used as freeze-drying stabilizer.
5. As a gas forming agent.
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MAGNESIUM STEARATE 46
Nonproprietary names: BP- Magnesium stearate Ph Eur-Magnesia stearate
USP NF- magnesium stearate.
Synonyms: Stearic acid magnesium salt,  Magnesium octadecanoate
Chemical name: Octdecanoic acid magnesium salt
Description: Magnesium stearate is a fine, white, precipitated, milled, impalpable
powder of   low bulk density, having a faint, characteristic odor and taste. The
powder is greasy to touch and readily adheres to skin.
Applications:
1. Magnesium stearate is widely used in cosmetics, foods and
pharmaceuticals.
2. It is primarily used as lubricant in capsule and tablet
manufacture at a concentration between 0.25-5.0 %
concentrations.
3. As an excipient, it is mainly used as directly compressible
tablet diluents.
4. Also used in micro sphere formulations
5. Used to absorb liquids, such as flavours in tabletting process.
MICRO CRYSTALLINE CELLULOSE 46
Nonproprietary Names
BP: Microcrystalline cellulose, JP: Microcrystalline cellulose,
PhEur: Cellulosum microcristallinu, USPNF: Microcrystalline cellulose
Synonyms
Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; crystalline cellulose; E460;
Emcocel; Ethispheres; Fibrocel; Pharmacel; Tabulose; Vivapur.
Chemical Name and CAS Registry Number: Cellulose [9004-34-6]
Empirical Formula and Molecular Weight: (C6H10O5)n _36 000 where n _ 220.
Functional Category: Adsorbent; suspending agent; tablet and capsule diluent;
tablet disintegrant.
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Uses :
Melting point: Chars at 260–2708C.
Moisture content: Typically less than 5% w/w. However,different grades may
contain varying amounts of water. Microcrystalline cellulose is hygroscopic.
Solubility: slightly soluble in 5% w/v sodium hydroxide  solution; practically
insoluble in water, dilute acids, and most organic solvents.
Applications in Pharmaceutical Formulation
 Primarily as a binder/diluent in oral tablet and capsule  Formulations where it
is used in both wet-granulation and Direct-compression processes. in
addition to its use as a Binder/diluent, microcrystalline cellulose also has
some lubricant and disintegrant properties that make it useful in Tableting.
 Microcrystalline cellulose is a purified, partially depolymerized cellulose
that occurs as a white, odorless, tasteless, crystalline powder composed of
porous particles.
LACTOSE ANHYDROUS 46
Nonproprietary Names: BP: Anhydrous lactose, JP: Anhydrous lactose
PhEur: Lactosum anhydricum, USPNF: Anhydrous lactose
Synonyms
Anhydrous Lactose NF 60M, Anhydrous Lactose NF Direct Tableting, Lactopress
Anhydrous,  lactosum,  lattioso, milk sugar, Pharmatose DCL 21, Pharmatose
DCL, saccharum lactis, Super-Tab Anhydrous.
Chemical Name: O-b-D-galactopyranosyl-(1!4)-b-D-glucopyranose
Empirical Formula and Molecular Weight: C12H22O11 342.30
S no Use Concentration (%)
1 Adsorbent 20–90
2 Antiadherent 5-20
3 Capsule binder/diluent 20-90
4 Tablet disintegrant 1-15
5 Tablet binder/diluent 20-90
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Functional Category: Binding agent; directly compressible tableting excipient;
lyophilization aid; tablet and capsule filler.
Applications in Pharmaceutical Formulation
Anhydrous lactose is widely used in direct compression tableting applications and as
a tablet and capsule filler and binder. Anhydrous lactose can be used with moisture-
sensitive drugs due to its low moisture content.
Description
Lactose occurs as white to off-white crystalline particles or powder. Several
different brands of anhydrous lactose are commercially available which contain
anhydrous b-lactose and anhydrous a-lactose. Anhydrous lactose typically contains
70–80% anhydrous b-lactose and 20–30% anhydrous a-lactose.
Melting point
223.08C for anhydrous a-lactose;
252.28C for anhydrous b-lactose;
232.08C (typical) for commercial anhydrous
Solubility: Soluble in water; sparingly soluble in ethanol (95%) And ether.
Specific Surface Area: 0.41m2/g for Pharmatose DCL 22; 0.37m2/g for Super-Tab
Anhydrous.
POLY VINYL PYROLLIDINE 46
Nonproprietary Names:
BP: Povidone, JP: Povidone, PhEur: Povidonum, USP: Povidone
Synonym
E1201, Kollidon, Plasdone, poly[1-(2-oxo-1-pyrrolidinyl)ethylene], polyvidone,
polyvinylpyrrolidone, PVP, 1-vinyl-2-pyrrolidinone polymer.
Chemical Name and CAS Registry Number
1-Ethenyl-2-pyrrolidinone homopolymer [9003-39-8]
Empirical Formula and Molecular Weight: (C6H9NO)n 2500–3 000 000
Approximate Molecular Weights for different grades of Povidone
K-value Approximate molecular weight
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Functional Category: Disintegrant; dissolution aid; suspending agent; tablet binder.
Description
Povidone occurs as a fine, white to creamy-white colored, odorless or almost
odorless, hygroscopic powder.
Melting point: softens at 1508C.
Moisture content: povidone is very hygroscopic, significant amounts of moisture
being absorbed at low relative humidities.
Solubility: Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol,
and water; practically insoluble in ether, hydrocarbons, and mineral oil. In water, the
concentration of a solution is limited only by the viscosity of the resulting
solution, which is a function of the K-value.
Applications in Pharmaceutical Formulation
 Although povidone is used in a variety of pharmaceutical formulations, it is
primarily used in solid-dosage forms. In tableting, povidone solutions are
used as binders in wet granulation processes.
 Povidone is used as a solubilizer in oral and parenteral formulations and has
been shown to enhance dissolution of poorly soluble drugs from solid-dosage
for forms. Povidone solutions may also be used as coating agents
Uses of Povidone
S no Use Use concentration
1 Carrier for drugs 10-25
2 Dispersing agent Up to 5
3 Eye drops 2-10
4 Suspending agent Up to 5
5 Tablet binder, tablet diluent, or coating agent 0.5-5
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5. PLAN OF WORK
The present study was carried by formulating and developing bi layer tablets of
Metformin Hcl Floating SR layer and Sitagliptin IR layer and evaluating them for in
vitro drug release profiles, post compression parameters and mechanism of drug
release.
The plan of the work in brief consists of the following steps :
Step – 1  Preformulation studies of Metformin Hcl And Sitagliptin Phosphate drug
substances.
 Description
 Melting point
 Solubility
 IR spectrum
 Determination of λ maximum by UV spectrum.
 Assay
 Drug excipient compatibility study
Step – 2  Construction of calibration curves for both Metformin Hcl And Sitagliptin
Phosphate by UV spectrophotometer.
Step – 3   Formulation of Metformin Hcl floating SR layer tablets by using HPMC
Sodium CMC.
Step – 4   Formulation of Sitagliptin IR layer by using Superdisintegrants.
Step – 5    Evaluation of Precompression Parameters of Metformin  Granules and
Sitagliptin  Blend.
Step – 6   Evaluation of Floating Behaviour, Swelling Study for Metformin tablets.
Step - 7  Disintegration test and Evaluation of Post compression parameters for both
tablets.
Step – 8   In vitro dissolution study of Metformin SR tablets andselecting the best
formulation from the results.
Chapter 5 Plan Of Work
Bilayer Floating Tablets Of Metformin Hcl And Sitagliptin Phosphate Page 61
Step – 9 In vitro dissolution study of sitagliptin IR tablets and selecting the best
formulation from the results.
Step – 10 Compression of the Bi layer tablet having with best formulations of
Metformin SR and Sitagliptin IR tablets respectively.
Step – 11 Evaluation of the bi layer tablets
 Post compression parameters of the bilayer tablets.
 Floating (or) In vitro buoyancy test.
 In vitro Disintegration test for Sitagliptin layer.
 In vitro dissolution study of  the bilayer tablets for the release of
Sitagliptin and Metformin Hcl.
 Swelling study.
Step – 12 Comparision of  in vitro drug release profiles of both  drugs with respective
marketed formulations.
Step - 13 Kinetic studies (or) fitting of in vitro drug release data into various model.
Step – 14 Stability Studies of bilayer tablets as per ICH guidelines.
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6. MATERIALS AND METHODS
6.1. A MATERIALS USED
Table – 01: List of Drugs and Excipients used in the study.
S.No Materials Manufacturers / Suppliers
1 Metformin hydrochloride Micro labs
2 Sitagliptin phosphate Micro labs
3 HPMC K 100M (Methocel) Vivimedpharma, Hyderabad
4 Sodium CMC Vivimedpharma, Hyderabad
5 PVP K30 Vivimedpharma, Hyderabad
6 Lactose Vivimedpharma, Hyderabad
7 Microcrystalline cellulose (Avicel) Vivimedpharma, Hyderabad
8 Sodium bicarbonate S.D Fine Chemicals, Mumbai
9 Magnesium stearate S.D Fine Chemicals, Mumbai
10 Iso propyl alcohol S.D Fine Chemicals, Mumbai
11 Pregelatinised starch S.D Fine Chemicals, Mumbai
12 Cross povidone S.D Fine Chemicals, Mumbai
13 Cross carmellose sodium Vivimedpharma, Hyderabad
14 Sodium starch glycollate Vivimedpharma, Hyderabad
15 Iron oxide – Red Vivimedpharma, Hyderabad
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6.1.B INSTRUMENTS USED
Table - 02: List of Equipments used in the study
S no Equipment / Instruments Manufacturer
1 Electronic Weighing Balance Mettler
2 Sieve no # 40 and  # 28 Jaico metals
3 Hot air oven Thermo lab
4 Tablet punching machine CJD3-3 Cadmach
5 Tablet Hardness Tester Inlap
6 Friability Tester USP (EF-2), Electro lab
7 Vernier caliper ICI
8 Dissolution Tester (USP type II) Lab India
9 Disintegration Tester USP Lab india
10 Melting Point Apparatus Systronic
11 UV-VIS. Spectrophotometer Lab india
12 Stability control oven( 40ºC/75 RH) Thermo lab
13 pH Meter Systronic
14
FT-IR Spectrophotometer
Spectrum RXI-FTIR  Perkin
Elimer
Chapter – 6 Materials And Methods
Bilayer Floating Tablets Of Metformin Hcl And Sitagliptin Phosphate Page 64
6.2 METHODOLOGY
6.2.1 PREFORMULATION STUDIES
Preformulation may be described as a phase of the dosage form development process
which consists of characterization of the physical, chemical and mechanical properties
of new drug substances, in order to develop stable, safe & effective dosage forms.
Here preformulation studies were conducted for both drugs Metformin Hydrochloride
and Sitagliptin Phosphate.
A) Identification and characterization of the drug
i . Description
The drug samples obtained were examined for their state, appearance, colour, odour etc.
ii . Melting point
The melting point of the drug substances was determined by using melting point
apparatus (PMP-D, Veego). The melting point was determined by introducing small
amount of substance in the capillary attached to graduated thermometer and constant
heat was applied with the assembly suspended in the paraffin bath. The drug samples
were tested in temperature range of 100-2500C and point at which drug melts was
noted. The melting points were reported in sections - 7.11 & 7.12.
iii . Solubility
Solubility of the Metformin Hydrochloride And Sitagliptin Phosphate were determined
in different solvents like water, 0.1 N Hcl, phosphate buffer pH 6.8, alcohol, acetone
etc.
IV. IR absorption spectrum
FT-IR spectra of drug samples were recorded using potassium bromide (KBr) pellet
method at resolution of 4cm-1 for its authentication and to study principle peaks using
FT-IR spectrophotometer (FT-IR 8400S, Shimadzu). Dry sample of drug and potassium
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bromide was mixed uniformly and filled into the die cavity of sample holder and an IR
spectrum was recorded. The identified peaks were compared with the principle peaks of
reported IR spectrum. Thus the samples were authenticated. The FT-IR spectra of
Metformin HCl and Sitagliptin phosphate were shown in Figures -7.1 & 7.8.
V. UV spectra
 UV- Spectrum of pure Metformin HCl was observed in 0.1 N Hcl ( pH 1.2 ) as
a medium. Drug (10 mg) was dissolved in 100 ml 0.1 N Hcl to obtain the stock
solution of concentration 100 µg/mL. From this stock solution, 1mL was
withdrawn and diluted upto 10 mL and resultant solution was scanned between
200-400 nm to determine its absorption maxima using UV- spectrophotometer
(labindia). It should give peak corresponding to its λmax at 233 nm. The UV
spectrum of Metformin HCl is shown in Fig – 7.2.
 UV- Spectrum of pure Sitagliptin Phosphate was taken in 0.1 N Hcl ( pH 1.2 )
as a medium. Drug (10 mg) was dissolved in 100 ml 0.1 N Hcl to obtain the
stock solution of concentration 100 µg/mL. From this stock solution, 1mL was
withdrawn and diluted upto 10 mL. and resultant solution was scanned between
200-400 nm using UV- spectrophotometer. It should give peak corresponding
to its λmax at 267 nm. The UV spectrum of Sitagliptin Phosphate is shown in fig
–7.9.
V. Assay
Metformin Hcl
 The assay procedure for authentification of Metformin HCl was carried out as
per Procedure reported in USP 30 NF 25 2007.
Procedure: Weigh accurately about 60 mg of Metformin HCl, dissolve in 4 ml
of anhydrous formic acid, add 50 ml of acetic anhydride and carry out non-
aqueous titration, determining the end-point potentiometrically. Perform a
blank determination and make any necessary correction.
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Each ml of 0.1 N Perchloric acid is equivalent to 0.008281 g of C4H11N5, HCl.
Sitagliptin Phosphate
Procedure: Different aliquots of working standard solutions containing 2‐10 μg of
STP was transferred into a series of serially numbered 10ml volumetric flasks. The
flasks were diluted to 10 ml with distilled water. The absorbance of the solution was
measured at 267 nm using water as a blank. The amount of sitagliptin phosphate present
in the sample was computed from the corresponding calibration curve.
6.2.2 PREPARATION OF CALIBRATION CURVE
A) Metformin Hcl
Preparation of 0.1 N Hcl: 85 ml of Hydrochloric Acid was taken and diluted with
water to 1000 ml to obtaine 0.1 N Hydrochloric Acid.
Procedure:
10 mg of pure Metformin Hcl was accurately weighed and transferred to 100 ml
volumetric flask. The drug was initially dissolved in 50 ml of 0.1 N Hcl Solution with
shaking and the volume was made up to the mark with the same solvent to obtain
standard stock solution A of concentration 100 µg/ ml. From the above stock solution
A 1 ml was withdrawn and transferred to 10 ml volumetric flask and was diluted up to
the mark with 0.1 N Hcl to obtain secondary stock B of concentration 10 µg/ ml.
Appropriate dilutions of the secondary  standard stock solution B  was done by
withdrawing 1,2,3,4,5 ml of samples from B and diluting with 0.1 N Hcl to get the
concentrations  of 1,2,3,4,5 µg/ ml. The absorbance of these working standard solutions
were obtained in the quantitative mode of the instrument at 233 nm which is the λ max
of Metformin Hcl. The absorbance of different concentration of Metformin Hcl are
reported Table no -7.2 and the calibration curve is shown in Fig -7.3 .
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B) Sitagliptin Phosphate
Preparation of 0.1 N Hcl: : 85 ml of Hydrochloric Acid was taken and diluted with
water to 1000 ml to obtain 0.1 N Hydrochloric Acid.
Procedure : 10 mg of pure Sitagliptin Phosphate was accurately weighed and
transferred to 100 ml volumetric flask. The drug was initially dissolved in 50 ml of 0.1
N Hcl with shaking and the volume was made up to the mark with the same solvent to
obtain standard stock solution A of concentration 100 µg/ ml. From the above stock
solution A 1,2,3,4,5,6,7….10 m samples were withdrawn and transferred to 10 ml
volumetric flasks and were diluted up to the mark with 0.1 N Hcl to obtain secondary
stock solutions having concentration 10,20,30,40,50,60,70…100 µg/ ml respectively.
The absorbance of these samples were measured  at 267 nm which is the λ max of
Sitagliptin Phosphate . The absorbance of different concentration of Sitagliptin
phosphate were  reported in Table no -7.3 and the calibration curve is shown in Fig –
7.10.
6.2.3 DRUG – EXCIPIENT COMPATIBILITY
The selected drug and polymers were characterized by FT-IR spectroscopy and
the FTIR spectra of the pure drug Metformin Hcl with used excipients like HPMC
K100M, sodium CMC, Microcrystalline cellulose, PVP K30, magnesium stearate etc.
and Sitagliptin Phosphate with excipients like crospovidone ,  croscarmellose sodium,
sodium starch glycolate and pre gelatinised starch were recorded to know the drug-
excipient interactions.
The instrument was operated under dry air purge and the scans were collected at
scanning speed 2 mm/sec with resolution of 4 cm-1 over the region 4000-400 cm-1. The
scans were evaluated for presence of principle peaks of drug, shifting and masking of
drug peaks and appearance of new peaks due to polymer interaction. The FT-IR
spectra of pure Metformin Hcl, Sitagliptin Phosphate and the spectra of drug excipient
mixtures were shown in fig – 7.4 -7.7 and 7.11 – 7.15 respectively.
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6.2.4 FORMULATION AND DEVELOPMENT
The proposed bi - layer tablet contains two layers. They are
1. Floating sustained release layer containing Metformin Hydrochloride.
2. An immediate release layer containing Sitagliptin.
6.2.4.1 FORMULATION OF METFORMIN HCL LAYER
Different formulations of sustained release floating tablets of Metformin Hcl
layer (F1-F10) were prepared by wet granulation method by using different excipients
Like HPMC K100 M, Sodium CMC as release retarding polymer, PVP K 30 as a
binder, Sodium Bicarbonate as an effervescent agent, Magnesium Stearate as a
lubricant..
The dose of Metformin Hcl for sustained release was taken as 500 mg based on the dose
calculation.
Dose Calculation
Total dose of Metformin for sustained release formulation was calculated by the
following equation using available pharmacokinetic data.
Dt= D(1 + 0.639 X t/t1/2)
Where, Dt=Total dose of Drug, D = Dose of immediate release part (250 mg),
t= time(hours) during which the sustained release is desired (12hours), t1/2= half-life of
the drug (6.2Hours).
Here, for Metformin Hcl 250 mg is the conventional dose. Therefore, dose of metformin
equivalent to 250 mg of Metformin Hcl is 213.5 mg.
Dt = 213.5(1+0.639X12/6.2)= 477.55 mg.
Hence, the dose of Metformin for sustained release tablet  was taken as 500 mg.
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Procedure for wet granulation:
Step 1 – Sifting:
Appropriate quantities of Metformin HCl, and excipients like HPMC K100 M, Sodium
CMC, PVP K 30 and Sodium Bicarbonate were measured accurately and all the
measured powders were sifted through Seive no # 40.
Step 2 – Dry Mixing:
The above sifted materials were mixed rapidly for 5 min and again passed through
sieve no 40.
Step 3 – Granulation:
Iso Propyl Alcohol having 2% w/v amount of PVP K‐ 30 was used as the granulating
solution and the solution was added to the mixture in step 2 and was kneaded for 2-5
min, then the kneaded mass was passed through sieve no # 20 to obtain the granules.
Step 4 – Drying Of Granules:
The granules obtained in step 3 were dried in a tray drier at 50°C for 2 hrs.
Step 5 – Lubrication:
The dried granules were lubricated uniformly with weighed quantities of magnesium
stearate.
Step 6 – Compression:
The above granules were compressed into tablets by CADMACH multi station tablet
compression machine by using 9 mm punch.
In Batch F1 to F3, HPMC K100M was used as the sustained release polymer
and in Batch F4 & F5 sodium CMC was used and in F6 – F8 combination of HPMC
K100M and sodium CMC was used as Polymer and in Batch F9 & F10 only HPMC
K100M was used as the release retarding polymer
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TABLE – 6.3: Formulations Of The Metformin Hcl Floating Sustained Release Layer
6.2.4.2 FORMULATION OF SITAGLIPTIN IMMEDIATE RELEASE LAYER
Different formulations of sitagliptin IR tablets containing the drug with
excipients like pre gelatinised starch, microcrystalline cellulose, cross povidone,
croscarmellose sodium,  sodium starch glycolate, poly vinyl pyrollidine, magnesium
stearate were prepared by Direct Compression method.
Procedure:
Step 01 – Sifting:
Sitagliptin and other excipients like pre gelatinised starch, microcrystalline cellulose,
cross povidone, croscarmellose sodium,  sodium starch glycolate, poly vinyl pyrollidine
were sifted through sieve no 40 #.
S
no
INGREDIENTS
(mg)
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
1 Metformin Hcl 500 500 500 500 500 500 500 500 500 500
2 HPMC K 100M 100 125 150 - - 100 100 100 150 150
3 Sodium CMC - - - 100 150 25 50 75 - -
6 PVP K30 30 30 30 30 30 30 30 30 30 30
7 Sodium
Bicarbonate
10 10 10 10 10 10 10 10 25 50
8 Magnesium
Stearate
5 5 5 5 5 5 5 5 5 5
9 Iso Propyl Alcohol q.s q.s q.s q.s q.s q.s q.s q.s q.s q.s
10 Total Weight 645 670 695 645 695 670 695 720 710 735
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Step 02 – Blending:
The sifted powders were thoroughly mixed for approximately 5 min and again passed
through sieve no 40 # for maintaining uniformity in particle size.
Step 03 – Lubricating:
Above mixture was lubricated for 2 min with Magnesium Stearate which was already
passed through sieve 60.
Step 04 – colouring:
The colour iron oxide red (0.125% w/w) was passed through the sieve number # 100
and added to the above mixture and blended uniformly to ensure uniform colour.
Step 05 – compression:
Then the tablets were compressed by using CADMACH multistation compression
machine with 6mm bi concave punches.
For Batches F1 to F3 crospovidone, F4 to F6 croscarmellose sodium and in F7 to F9
sodium starch glycolate were used as superdidintegrants.
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Table – 04: Formulations Containing Sitagliptin Immediate Release Layer (in mgs)
6.2.4.3 EVALUATION OF PRE COMPRESSION PARAMETERS OF BOTH
TABLETS
Several Pre compression parameters of Metformin Hcl granules and Sitagliptin blend
were evaluated as follows:
a) Angle of Repose
Angle of repose has been defined as the maximum angle possible between the
tangent to the surface of pile of powder and horizontal plane. The angle of repose for the
granules of each formulation was determined by the funnel method. The granules mass
was allowed to flow out of the funnel orifice on a plane paper kept on the horizontal
surface. This forms a pile of granules on the paper. The angle of repose was calculated
S no INDREDIENTS (mg) S1 S2 S3 S4 S5 S6 S7 S8 S9
1 Sitagliptin 50 50 50 50 50 50 50 50 50
2 Pre gelatinised Starch 100 100 100 - - - - - -
3 Microcrystalline
Cellulose
80 75 72.5 100 100 100 30 150 87.5
4 Lactose - - - 80 75 72.5 150 27.5 87.5
5 Crospovidone 5 10 12.5 - - - - - -
6 Croscarmellose
Sodium
- - - 5 10 12.5 - - -
7 Sodium Starch
Glycolate
5 7.5 10
8 PVP K30 10 10 10 10 10 10 10 10 10
9 Magnesium Stearate 5 5 5 5 5 5 5 5 5
10 Iron Oxide Red q.s q.s q.s q.s q.s q.s q.s q.s q.s
11 Total 250 250 250 250 250 250 250 250 250
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by substituting the values of the base radius ‘R’ and pile height ‘H’ in the following
equation.
Table – 05 Relationship between angle of repose (θ) and flowability
b) Bulk Density
The bulk density was obtained by dividing the mass of a powder by the bulk
volume in cm3. It was calculated by using equation given below:
ρb = M / V0
Where, ρb = bulk density
M = weight of sample in grams
V0 = Apparent unstirred volume
c) Tapped Density
The tapped density was obtained by dividing the mass of a powder by the tapped
volume in cm3. It was calculated by using equation given below:
ρt = M / Vf
Angle of Repose (θ) FLOWABILITY
< 20 Excellent
20 – 30 Good
30 – 34 Passable
> 40 Very poor
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Where, ρt = Tap density
M = weight of sample in grams
Vf = final Tap volume
d) Carr’s Index: The Carr’s index is also called as the compressibility index. The
Carr’s index is determined from the tapped density and poured density (bulk density) as
per the formula given below.
Carr’s index (%) = Tapped density- bulk density × 100
Tapped density
Table – 06 Relationship between % Compressibility and Flowability
% Compressibility Flowability
5 – 15 Excellent
12 – 16 Good
18 – 21 Fair  to Passable
23 – 35 Poor
33 – 38 Very Poor
> 40 Extremely Poor
e) Hausner ratio: Hausner ratio is determined from the ratio of tapped density to
poured density using   formula given below.
Hausner ratio = Tapped density
Poured density
Table no - 07  Hausner’s Ratio Limits
Flow character Hausner’s Ratio
Excellent 1.00-1.11
Good 1.12-1.18
Fair 1.19-1.25
Passable 1.26-1.34
Poor 1.34-1.45
Very poor 1.46-1.59
Very, very poor >1.60
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The Angle of repose, Bulk density, Tap density, Carr’s index and Hausner ratio of both
the formulations were reported in sec -7.2
6.2.5 EVALUATION OF THE COMPRESSED TABLETS
6.2.5.1 In vitro buoyancy study of Metformin Hcl floating tablets
In vitro buoyancy studies were performed to determine the floating lag time and
total floating time of the tablets. They are performed as per the method described by
Rosa et al. The tablets were placed in 100 ml beaker containing 0.1N hydrochloric acid
of pH 1.2 at temperature of 37 οC.
Floating lag time: The time required for the tablet to rise to the surface of the beaker
and float was determined as the floating lag time.
Total floating time
The total time duration for which the tablet constantly remained on the surface of the
medium was determined as the total floating time.
Tablet density
Tablet density is an important parameter for the floating tablets. The tablet will float
when its density is less than that of the gastric fluids (1.004g/cc). when tablet comes in
contact with the gastric fluid it will float by releasing the co2 gas ( because of the
effervescent agent sodium bi carbonate) as its density is less than gastric fluids.
The density of the tablet was determined as follows :
D = m/v
D = density
M = mass or weight of the tablet
V = volume of the tablet (cc) ( h )
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6.2.5.2 Swelling Study of Metformin Hcl Tablets
The swelling behaviour of a dosage form is measured by studying its weight
gain or water uptake. Water uptake is measured in terms of percent weight gain, as
given by the equation. The individual tablets were kept in 50 ml of water. Tablets were
taken out after every 1 hr up to 5 hrs, blotted with filter paper to remove water on the
surface and weighed accurately. The % swelling (or) water uptake (%WU) was
measured as:
%WU = X 100
Wt = Weight of dosage form at time t.
W0 = Initial weight of dosage form.
6.2.5.3   In-vitro Disintegration test for Sitagliptin Tablets
The in-vitro disintegration test was performed to determine the disintegration
time. A tablet was placed in each of the six tubes of the apparatus and one disc was
placed on each tube. The time in seconds taken for complete disintegration of the tablet
with no palatable mass remaining in the apparatus was measured.
6.2.5.4 Evaluation of Post Compression Parameters
The compressed Metformin Hcl SR tablets and Sitagliptin IR tablets were
evaluated for the post compression parameters like Hardness, Friability, Weight
Variation, Thickness, Drug Content Uniformity etc.
a) Shape of Tablets:
Tablets were examined under the magnifying lens for the shape of the tablet.
b) Tablet Dimensions:
Thickness and diameter were measured using a calibrated vernier caliper. Tablets of
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each formulation were picked randomly and thickness was measured individually.
c) Hardness: Hardness is the ability of the tablet to withstand the mechanical shocks
under conditions of storage, transportation and handling before usage by a patient and it
depends on the strength of tablet. The hardness of tablet of each formulation was
measured by Pfizer hardness tester. The hardness was measured in terms of kg/cm2. For
each batch three tablets were picked randomly and tested for hardness tested.
d) Friability
Friability is the measure of tablet strength. Roche friabilator was used for testing
the friability using the following procedure.
Procedure: Twenty tablets were weighed accurately and placed in the tumbling
apparatus that revolves at 25 rpm dropping the tablets through a distance of six inches
with each revolution. After 4 min (or) 100 revolutions, the tablets were weighed and the
% friability was calculated measured using the formula.
% Friability  =   Initial weight of tablets- Final weight of tablets × 100
Initial weight of tablets
Limits: Percentage friability of tablets less than 1% is considered acceptable.
e) Weight variation test
USP procedure for weight variation test was followed which is as follows:
Twenty tablets were randomly selected from each batch and individually weighed by
using Electronic balance (Shimatzu). The average weight and standard deviation of
twenty tablets were calculated. Not more than two of the individual weights should
deviate from the average weight by more than the % deviation mentioned in the table
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Table – 06 Limits for weight variation
S no Average weight of tablet (X mg) Percentage deviation
allowed
1
2
3
130 mg or less
130-324 mg
More than 324 mg
10
7.5
5
% Maximum positive deviation = ( WH – A/A ) ×100
% Minimum negative deviation = (A – WL/ A ) × 100
Where
WH = highest weight in mg.
WL =  lowest weight in mg.
A =    average weight of tablet in mg.
f) Drug Content Uniformity
Metformin Hcl
The Drug content uniformity of Metformin HCl was carried out as per Procedure
reported in I.P 1996.
Procedure:
From each formulation 5 tablets were seleted randomly, crushed and powdered. The
powder equivalent to 60 mg of Metformin Hcl was weighed and dissolved in 4 ml of
anhydrous formic acid, 50 ml of acetic anhydride was added and non-aqueous titration
was carried out, determining the end-point potentiometrically. A blank determination
was made and necessary correction was made.
Each ml of 0.1 M perchloric acid is equivalent to 0.008281 g of C4H11N5, HCl
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Sitagliptin Phosphate
Standard preparation
10 mg of sitagliptin was weighed and dissolved in 100 ml water to obtain the stock
solution of concentration 100 µg/mL. From this stock solution, 1mL was withdrawn and
diluted up to 10 mL with water to obtain the concentration of 10 μg/ml.
Sample preparation:
From each formulation 5 tablets were combined and thoroughly crushed. An
amount of tablet powder equivalent to average weight of one tablet (100mg) was
accurately weighed and transferred to a 100 ml volumetric flask, to this 30 ml double
distilled water was added. The content of the flask was sonicated for 15 min and the
volume was made up to mark with water. The solution was filtered filter through
Whatmann filter paper No. 40. Appropriate solutions were prepared by taking suitable
aliquots and diluting them with double distilled water to give final concentration (10
μg/ml). Then the absorbance of these solutions was measured at 267 nm.
Percentage drug content was calculated as follows:
% drug content =
At = absorbance of test sample
As = absorbance of the standard preparation
Ct = concentration of the test sample
Cs = concentration of the standard preparation
P = standard potency (99.7)
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6.2.5.5 IN VITRO DISSOLUTION STUDY
A) Metformin Hcl Floating SR Tablets
In vitro dissolution study was performed using USP Dissolution Testing
Apparatus II (Electrolab). The dissolution test was performed using 900 ml of 0.1 N
HCL, at 37 ± 0.50C with paddle agitation at 100 rpm. 10 ml samples were withdrawn
from the dissolution vessels at the time intervals of 1, 2, 4, 6, 8, 10,12hrs and the
samples were replaced with fresh dissolution medium equilibrated at the same
temperature to maintain the volume. The samples were filtered through Whatman filter
paper no. 41.The samples collected were diluted appropriately to attain the
concentration of 10 µg/ml with the same medium. Samples were then analyzed by UV
spectrophotometer at 233 nm. Then the % drug release was calculated from the
absorbance values and is reported in sec 7.3.4.
Details of Dissolution Test
Apparatus                                                        : USP Type – II (Paddle)
Volume of medium                                         : 900 ml
Temperature                                                    : 37± 0.5 οC
Paddle Speed                                                   : 100 rpm
Dissolution medium used                                : 0.1 N HCL
Aliquot taken at each time interval                 : 10 ml
B) Sitagliptin Phosphate IR Tablets
In vitro dissolution study was performed using USP Dissolution Testing
Apparatus II (Electrolab). The dissolution test was performed using 900 ml of 0.1 N
HCL, at 37 ± 0.50C with paddle agitation at 50 rpm. 10 ml samples were withdrawn
from the dissolution vessels at the time intervals of 5, 10, 15, 20, 30, 40, 60 min and the
samples were replaced with fresh dissolution medium equilibrated at the same
temperature to maintain the volume. The samples were filtered through Whatman filter
paper no. 41.The samples collected were diluted appropriately to attain the
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concentration of 10 µg/ml with the same medium. Samples were then analyzed by UV
spectrophotometer at 267 nm. Then the % drug release was calculated from the
absorbance values and is reported in sec 7.4.3 .
Details of Dissolution Test:
Apparatus                                                        : USP Type – II (Paddle)
Volume of medium                                         : 900 ml
Temperature                                                    : 37± 0.5 οC
Paddle Speed : 50 rpm
Dissolution medium used                                : 0.1 N HCL
Aliquot taken at each time interval                 : 10 ml
6.2.5.6 Selection of the Best Formulations
From the dissolution profiles of both the drugs best formulations were selected
from Metformin Hcl floating SR tablets and Sitagliptin IR tablets formulations by
comparing them with the marketed formulations.
GLUCOPHAGE XR (500MG) tablets and JANUVIA (50MG) tablets were used as the
marketed samples for Metformin and Sitagliptin respectively.
6.2.6 PREPARATION OF BI LAYER TABLETS
Bi‐layer tablets of Metformin and Sitagliptin were prepared by taking the best
formulations from Metformin Hcl SR floating tablets and Sitagliptin IR tablets.
Granules of Metformin layer were first introduced into the die cavity, a slight
compression was made and then Sitagliptin blend was introduced into the die cavity
followed by final compression with optimum hardness to form the bi layer tablets. Here
compression was made by using 16 station tablet compression machine (Cadmach,
India) with 12 mm capsule shaped punches.
Only one batch of the bi layer tablets containing best formulations from both layers
were prepared and evaluated for various physical properties and dissolution profile was
compared with respective marketed formulations.
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6.2.6.1 EVALUATION OF THE BILAYERED TABLETS
A ) Post Compression Parameters of The Bi Layered Tablets
The prepared bi layer tablets of Metformin Hcl and Sitagliptin were evaluated for
the following physic chemical properties
a) Shape of Tablets
Tablets were examined under the magnifying lens for the shape of the tablet.
b) Tablet Dimensions
Thickness and diameter were measured using a calibrated vernier callipers . Bi layer
Tablets were picked randomly and thickness was measured individually.
c) Hardness
Hardness is the ability of the tablet to withstand the mechanical shocks under
conditions of storage, transportation and handling before usage by a patient and it
depends on the strength of tablet. The hardness of tablet of each formulation was
measured by Pfizer hardness tester. The hardness was measured in terms of kg/cm2. For
each batch three tablets were picked randomly and tested for hardness tested.
d) Friability
Friability is the measure of tablet strength. Roche friabilator was used for testing
the friability using the following procedure.
Procedure: Twenty tablets were weighed accurately and placed in the tumbling
apparatus that revolves at 25 rpm dropping the tablets through a distance of six inches
with each revolution. After 4 min (or) 100 revolutions, the tablets were weighed and the
% friability was calculated measured using the formula.
% Friability = Initial weight of tablets- Final weight of tablets × 100
Initial weight of tablets
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Limits: Percentage friability of tablets less than 1% is considered acceptable.
e) Weight variation test
USP procedure for weight variation test was followed which is as follows:
Twenty tablets were randomly selected from each batch and individually weighed
by using Electronic balance (Shimatzu). The average weight and standard deviation of
twenty tablets were calculated. Not more than two of the individual weights should
deviate from the average weight by more than the % deviation mentioned in the table
Table – 06 Allowable limits for weight variation
% Maximum positive deviation = ( WH – A/A ) ×100
% Minimum negative deviation = (A – WL/ A ) × 100
Where
WH = highest weight in mg.
WL =  lowest weight in mg.
A =    average weight of tablet in mg.
f) Drug content of the Bilayer tablets
Twenty tablets were accurately weighed and crushed to fine powder. Powder
equivalent to 10 mg of Metformin HCl and 1mg of Sitagliptin was weighed and
dissolved in distilled water, sonicated for 10 min and filtered through Whatman’s filter
paper no.41. After rejecting first few ml, different concentrations of tablet sample were
S no Average weight of tablet (X mg) Percentage deviation
Allowed
1
2
3
130 mg or less
130-324 mg
More than 324 mg
10
7.5
5
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prepared by serial dilution technique and scanned over the range of 400-200 nm in
multi-component mode and analyzed at 233 and 267 nm wavelength.
6.2.6.2 In-Vitro Dissolution Study Of The Bi Layered Tablet
In vitro dissolution study of the bi- layer tablet containing Metformin Hcl SR floating
layer and Sitagliptin immediate release layer was performed as follows:
The dissolution was performed over a 12 hr period for bi layer tablets using USP
type II (paddle) Dissolution Testing Apparatus (Electrolab). 900ml of 0.1N Hcl was
used as dissolution medium agitated at 100 RPM, at temperature of 37± 0.5 0 C. 10 ml
samples were withdrawn at 5,10,15,20,30,40,60 min for 1 hr to estimate the release of
Sitagliptin, and at 1, 2, 4, 6, 8, 10, 12 hrs for estimating Metformin release. Same
volume of dissolution medium was replaced at every time interval, Samples were
filtered by whatman filter paper no. 41. The samples were analyzed for Metformin Hcl
and Sitagliptin by UV Spectrophotometry at their respective λ max values 233 nm and
267 nm.
The samples collected for first hour were analyzed for Sitagliptin content at 267 nm in
UV spectrophotometer by keeping the solution containing Metformin Hcl formulation
as blank to minimize the interference.
The samples collected for 1 – 12 hrs were analyzed for the release of Metformin Hcl at
233 nm in UV spectrophotometer by keeping the solution containing Sitagliptin
formulation as blank to minimize the interference.
Conditions of Dissolution Test:
 Apparatus : USP Type – II (Paddle)
 Volume of medium : 900 ml
 Temperature : 37± 0.5 οC
 Paddle Speed : 100 rpm
 Dissolution medium used : 0.1 N Hcl (pH 1.2)
 Aliquot taken at each time interval : 10 ml
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From the absorbance values obtained in above steps cumulative % drug release of
both Metformin Hcl and Sitagliptin were calculated.
6.2.6.3 Comparative Study
From the prepared bi layer tablet the in vitro drug release profile of the two
formulations i.e Metformin Hcl floating SR layer and Sitagliptin IR layer were
compared with their respective marketed tablets.
6.2.7 Kinetic Studies for estimating the mechanism of drug release
The methods of approach to investigate the kinetics of drug release from controlled
release formulation can be classified into three categories:
 Statistical methods: (Exploratory data analysis method, repeated measures
design, multivariate approach ).
 Model dependent methods : (Zero order, first order, Higuchi, Korsmeyer-
Peppas model,  Hixson Crowell, Baker-Lonsdale model, etc)
 Model independent methods : (Difference factor (f1), similarity factor (f2) )
To analyze the mechanism of the drug release, the in vitro dissolution data obtained was
fitted into the following models:
1) Zero-order model
Drug dissolution from dosage forms that do not disaggregate and release the drug
slowly can be represented by the equation:
Q0 n Qt = K0t (1)
Rearrangement of equation (1) yields:
Qt = Q0 + K0t (2)
Where: Qt is the amount of drug dissolved in time t,
Q0 is the initial amount of drug in the solution (most times, Q0 = 0) and
K0 is the zero order release constant expressed in units of concentration/time.
Chapter – 6 Materials And Methods
Bilayer Floating Tablets Of Metformin Hcl And Sitagliptin Phosphate Page 86
To study the release kinetics, data obtained from in vitro drug release studies were
plotted as Cumulative amount of drug released versus time
2) First order model
This model has also been used to describe absorption and/or elimination of some drugs,
although it is difficult to conceptualize this mechanism on a theoretical basis. The
release of the drug which followed first order kinetics can be expressed by the equation:
dc/dt = - Kc ---(3)
Where K is first order rate constant expressed in units of time-1.
Equation (3) can be expressed as:
log C = log C0 n Kt / 2.303 (4)
Where C0 is the initial concentration of drug,
k is the first order rate constant, and
t is the time .
The data obtained are plotted as log cumulative percentage of drug remaining vs. time
which would yield a straight line with a slope of n K/2.303
3) Higuchi model:
The first mathematical model aimed to describe drug release from a matrix system was
proposed by Huguchi in 1961 . This model is based on the hypotheses that (i) initial
drug concentration in the matrix is much higher than drug solubility; (ii) drug diffusion
takes place only in one dimension (edge effect must be negligible); (iii) drug particles
are much smaller than system thickness; (iv) matrix swelling and dissolution
arenegligible; (v) drug diffusivity is constant; and (vi) perfect sink conditions are
always attained in the release environment.
In a general way it is possible to simplify the Higuchi model as :
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f t = Q = KH t 1/2
where,
KH is the Higuchi dissolution constant
The data obtained were plotted as cumulative percentage drug release versus square
root of time.
4) Korsmeyer- Peppas model:
Korsmeyer et al. (1983) derived a simple relationship which described drug release
from a polymeric system equation .
Mt / M∞ = K tn.
where
Mt / M∞ is a fraction of drug released at time t, k is the release rate constant and n is
the release exponent. The n value is used to characterize different release for cylindrical
shaped matrices. To study the release kinetics, data obtained from in vitro drug release
studies were plotted as log cumulative percentage drug release versus log time.
S no Release exponent (n) Drug transport mechanism
1 0.5 Fickian diffusion
2 0.45 < n = 0.89 Non -Fickian transport
3 0.89 Case II transport Zero order release
4 Higher than 0.89 Super case II transport
6.2.7 Stability Studies
The purpose of stability testing is to provide evidence on how the quality of a
drug substance or drug product varies with time under the influence of a variety of
environmental factors such as temperature, humidity and light and to establish a re-
testing for the drug substance or a shelf-life for the drug product and recommended
storage conditions.
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The storage conditions used for stability studies were accelerated condition
(40oC± 2oC/75% ± 5% RH) and room temperature (30oC± 2oC/65% ± 5% RH).
Stability study was carried out for the optimized formulation. Tablets of optimized
formulation were striped packed and kept in stability chamber for 3 months on above
mention temperature.
Tests performed
1. Dissolution profile
2. Drug content uniformity
3. Test for other physical parameters
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7.  RESULTS AND DISCUSSION
In the present study bi layered tablets were prepared by combining Metformin
hydrochloride floating sustained release layer and Sitagliptin immediate release layer.
7.1 PREFORMULATION STUDIES
7.1.1 METFORMIN HYDROCHLORIDE
A) Identification and characterization of the drug
i) Description
The sample was found to odorless, white, crystalline, hygroscopic bitter powder.
ii) Melting point
Melting point of the pure Metformin was found to be 223o-226o C which was within
the limit as per the IP 1996.
iii) Solubility
Freely soluble in water, slightly soluble in alcohol, practically insoluble in acetone
and in methylene chloride.
IV) IR absorption spectrum
FT-IR spectrum of pure drug sample which was recorded using potassium bromide
(KBr) pellets method was as follows:
Fig – 7.1: FT-IR spectrum of Metformin Hydrochloride
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Table – 7.1 Data showing Observed and Reported peaks of Metformin Hcl.
V) UV spectra
UV- Spectra of pure Metformin Hcl was obtained from UV- Spectrophotometer and the
absorption maximum was found to be 233 nm.
Fig – 7.2 UV spectrum of Metformin Hcl
The spectrum shows that the absorption maximum of Metformin Hcl is at 233 nm with
absorbance of 0.854.
VI) Assay
The obtained sample of Metformin Hcl was found to be 99.76% w/w pure by assay
method.
Functional group
Vibrational    Frequencies cm-1
Observed peaks Reported peaks
N-H deformation 1624.12 cm-1 1630  cm-1
Asymmetric NCN stretch 1570.11 cm-1 1565 cm-1
CH3  Asymmetric
deformation
1473.66 cm-1,     1444.73 cm-
1, 1415.66 cm-1
1470, 1440, 1410 cm-1
C-N stretch 1062.81 cm-1 1060cm-1
CH3 rock 937.44 cm-1 940 cm-1
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From the above results of drug characterization study it was observed that the
sample of Metformin Hcl is pure and complies the Indian Pharmacopeial standards.
B) Calibration Curve For Metformin Hcl
The calibration curve of the Metformin Hcl was plotted in by measuring
Absorbance of different concentrations of samples (0-30 µg/ml) was measured at 233
nm. The regression coefficient was found to be 0.999 with slope value 0.087 .The
results indicate that there is a linear relationship between concentration and absorbance
and obey beer’s Lambert’s law.
y = 0.087x + 0.002
Table – 7.2 Data for calibration curve showing absorbance at 233 nm
Fig No – 7.3 Calibration curve of Metformin Hcl
S no Concentration (µg/ml) Absorbance at 233nm
1 0 0.00
2 1 0.09
3 2 0.18
4 3 0.265
5 4 0.357
6 5 0.434
Slope 0.087
Regression coefficient 0.999
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C) Drug – Excipient Compatibility
FTIR Spectra of Pure Metformin HCl, HPMC K100M, sodium CMC, PVP K-30,
lactose  and the physical mixture of Metformin + HPMC K100M + sodium CMC +
PVP K-30 were shown in Fig no: 7.4 to 7.7 .
Fig No -7.4 FT-IR spectrum of HPMC K100M
Fig No –7. 5 FT-IR spectrum of Sodium CMC
Fig no –7. 6   FT-IR spectrum of   PVP K30
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Fig No – 7.7 FT-IR spectrum of Metformin + HPMC K100M + sodium CMC+
PVPK30
From the Figure no 7.7 - It was confirmed that there is no interaction between drug
and polymers because the IR spectra of all physical mixtures retains the principal drug
peaks at :- 1624.12, 1570.11, 1062.81, 937.44 cm-1
7.1.2 SITAGLIPTIN PHOSPHATE
A) Identification And Characterization
i) Description
Sitagliptin phosphate monohydrate is a white to off-white, crystalline, non-hygroscopic
powder
ii) Melting point
The melting point of Sitagliptin phosphate was found to be 198o-202o C which implies
the purity of the drug.
iii) Solubility: It is slightly soluble in methanol, very slightly soluble in ethanol,
acetone, and acetonitrile, and insoluble in isopropanol and isopropyl acetate. It is a BCS
class 1 drug with high aqueous solubility and high permeability.
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iv) IR absorption spectrum
FT-IR spectrum of Sitagliptin Phosphate drug sample was recorded using potassium
bromide (KBr) pellet method and is as follows:
Fig no – 7.8 FTIR Spectrum of Sitagliptin Phosphate
Principle drug peaks were found at 1018.45, 1066.62, 1637.62, 3050.52, 3323.46 cm-1
V) UV spectra
UV- Spectra of pure Sitagliptin Phosphate was taken in 0.1N Hcl as the medium.
Sample of 10µg/ml was scanned over wave length range of 400-200 nm.
Fig no –7.9 UV Spectum of Sitagliptin Phosphate.
Thus from the spectrum the absorption maximum was found to be 267 nm.
VI) Assay
The obtained sample of Sitagliptin Phosphate was found to be 99.76% w/w pure.
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From the above results of drug chracterization study it was observed that the sample of
Sitagliptin Phosphate was pure and complies the Indian pharmacopial standards.
B) Calibration Curve For Sitagliptin Phosphate
Table No –7. 3 Calibration curve of Sitagliptin phosphate at 267 nm.
Concentration (µg/ml) Absorbance (nm)
0 0.00
10 0.037
20 0.073
30 0.111
40 0.149
50 0.186
60 0.221
70 0.26
80 0.296
90 0.332
100 0.371
Regression coefficient 1.00
Fig no – 7.10 Calibration curve of Sitagliptin Phosphate
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C) Drug – Excipient Compatibility
Fig no –7.11 FTIR Spectrum Of pure Sitagliptin Phosphate
Table no – 7.4 Data of Infra Red peaks of Sitagliptin Phosphate.
Fig no - 7.12 FTIR Spectrum of Sodium Starch Glycollate
Functional group
Vibrational    Frequencies  cm-1
Observed peaks Reported peaks
C-F str 1018.45 cm-1 1016.34 cm-1
C = O str 1637.62 cm-1 1635.50 cm-1
N tertiary amine str 1066.71 cm-1 1068.45 cm-1
AR – CH str 3050.52 cm-1 3047.42 cm-1
C =NH str 3323.46 cm-1 3320.65 cm-1
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Fig no – 7.13 FTIR spectrum of crosspovidone
Fig no –7.14 FTIR Spectrum of PVP K30
Fig no – 7.15   FTIR Spectrum of Sitagliptin + SSG + Crosspovidone + CCS +
PVP K30
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7.2 EVALUATION OF PRE COMPRESSION PARAMETERS
A) Evaluation of Metformin Hydrochloride  Granules
Table No – 7. 4 Pre Compression Parameters of Metformin Hcl Granules
Formulation
code
Angle of
Repose (θ)
(± SD)
Bulk Density
(g/cc)
(± SD)
Tapped
Density
(g/cc) (± SD)
Carr’s Index
(%)
(± SD)
Hausner
ratio
(± SD)
F1 20.80±0.11 0.754±0.07 0.878±0.05 15.09±0.06 1.1644±0.05
F2 20.06±0.08 0.781±0.09 0.899±0.09 15.10±0.05 1.1510±0.07
F3 22.33±0.16 0.843±0.09 0.9302±0.11 15.68±0.09 1.1055±0.05
F4 22.97±0.12 0.735±0.12 0.836±0.08 14.52±0.06 1.1374±0.09
F5 20.68±0.09 0.764±0.14 0.891±0.09 16.62±0.13 1.1662±0.06
F6 22.16±0.11 0.782±0.08 0.902±0.08 15.34±0.08 1.1542±0.09
F7 21.83±0.12 0.767±0.09 0.883±0.13 15.12±0.11 1.1512±0.07
F8 21.62±0.09 0.781±0.12 0.895±0.09 14.59±0.05 1.1459±0.05
F9 20.85±0.13 0.792±0.15 0.910±0.11 14.89±0.05 1.1489±0.07
F 10 21.75±0.13 0.751±0.17 0.845±0.16 14.58±0.05 1.1251±0.07
(n=3, ± S.D) (S.D= Standard deviation)
The dried granules were evaluated for various granule properties as shown in table
 Angle of repose
Angle of repose for the granules of F1-F9 was found to be 20.06 - 22.970, which
indicates good flow property
 Carr’s index
The carr’s index for the granules of F1-F9 was found to be 14.52 -16.62 %,
which shows good flowing properties.
 Hausner’s Ratio
Hausner ratio was found to be 1.1055 – 1.1662 it indicates good flow properties
of the granules.
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B) Evaluation of Sitagliptin Blend
The directly compressible blend of different formulations of Sitagliptin was
evaluated for angle of repose, Bulk and Tapped density, Compressibility index,
Hausner's ratio. It showed that the results of all formulations of the granules were within
limits and thus it confirmed that the granules have good flow property.
Table No – 7.5 Data for Pre Compression Parameters of Sitagliptin Blend
Formulatio
n code
Angle of
repose (θ)
Mean ±S.D
Bulk density
(gm/cc)
Mean±S.D
Tapped
density
(gm/cc) Mean
±S.D
Compressibilit
y index
Mean ±S.D
Hausner's
ratio
Mean ±S.D
F1 25.58±0.31 0.74±0.01 0.99±0.02 17.64±1.2 1.40±0.02
F2 25.08±0.45 0.78±0.08 0.98±0.01 16.21±1.62 1.32±0.02
F3 24.47±0.21 0.78±0.06 0.96±0.08 16.66±0.79 1.15±0.01
F4 23.72±0.23 0.85±0.047 0.98±0.04 13.31±0.78 1.15±0.01
F5 23.40±0.15 0.86±0.047 0.99±0.04 12.50±0.44 1.14±0.05
F6 23.29±0.17 0.86±0.022 0.97±0.04 11.38±1.20 1.13±0.01
F7 22.68±0.09 0.88±0.047 0.98±0.01 13.84±0.90 1.12±0.01
F8 22.77±0.15 0.87±0.098 0.99±0.04 11.49±0.53 1.13±0.06
F9 22.49±0.08 0.88±0.021 0.98±0.01 12.54±0.42 1.12±0.05
(n=3, ± S.D) (S.D= Standard deviation)
 Angle Of Repose
The angle of repose of all the 9 formulations was in the range of
22.49±0.08 to 25.58±0.31 which shows the good flow property of the
sitagliptin immediate release blend.
 Bulk And Tapped Density
The bulk and tapped density values were in the range of 0.74 -
0.88(gm/cc), and 0.97 - 0.99 (gm/cc), respectively.
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 Compressibility index:
The carr’s index (or ) Compressibility index for the blend of F1-F9 was
found to be in the range of 11.38-17.64 showing excellent to good flow
properties.
 Hausner’s Ratio
Hausner ratio was found to be in the range of 1.12- 1.40. It indicates
good flow properties of the blend.
7.3 EVALUATION OF METFORMIN HCL FLOATING SR TABLETS
7.3.1 Floating Behavior / In Vitro Buoyancy Test
Compositions of the buoyant layer for floating testing were shown in Table 6.3
.When the tablet was immersed in a 0.1 N Hcl solution at 37 0C, it sank at once in the
solution and the carbon dioxide gas started to generate from the floating layer
containing sodium bi-carbonate due to a chemical reaction. Each formulation started to
float at different floating lag times. The floating tablets slowly swelled due to the
presence of hydrophilic water swellable polymers like HPMC K100M and sodium
CMC.
All the formulations (F1 – F8) having 10 mg sodium bi carbonate floated around 4.8 to
7.0 min depending upon their apparent viscosity. The formulations F9 and F10
containing 25 mg and 50mg have shown the floating lag times of 3.0, 2.5 min
respectively. This shows that increase in sodium bi carbonate concentration decreases
floating lag time. The total floating times of all the formulations were above 24 hrs. The
formulations F9 & F10 shown less total floating time due to the increase in the
concentration of the effervescent agent.
7.3.2 Tablet Density
The density values of all the formulations were measured and were found to be in the
range of 0.845 g/cc to 0.933 g/cc. Since the density of all the tablets was less than that
of gastric fluids they have shown good floating property.
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Table No – 7.6 Results For In Vitro Buoyancy Test and Tablet Density
of the Metformin Hcl Tablets.
7.3.3 Swelling study
Table No – 7.7 Percentage Swelling Index of Metformin Hcl Tablets.
S
no
Time
(hr)
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
1 1 20.27 22.43 26.21 18.48 20.11 18.06 19.24 20.64 21.56 22.64
2 2 36.09 44.60 45.12 30.12 33.16 29.18 30.19 32.72 35.46 34.87
3 3 51.02 55.57 59.56 47.23 48.32 46.70 49.12 52.16 45.42 44.73
4 4 62.47 72.22 73.89 54.42 60.06 60.04 62.21 63.09 59.42 60.24
5 5 72.09 85.11 85.06 63.15 71.51 73.56 74.79 75.99 70.43 71.56
6 6 90.26 94.56 95.45 80.12 82.45 95.76 96.61 97.52 86.34 87.23
In the present study, F1 – F3 has HPMC K100 M shows more swelling than
F4 & F5 having Sodium CMC because of high viscosity of HPMC. Then from F6-F9
the combination of two polymers increases swelling due to the synergistic increase in
viscosity. Higher swelling index was found for tablets of batch F8 containing HPMC
K100 M (100mg) and sodium CMC (75mg). Thus, the viscosity of the polymer had
major influence on swelling process, matrix integrity, as well as floating capability,
S No Formulations
code
Tablet density
(g/cc)
Floating lag time
(min) average (n-3)
Total Floating
Time (Hr)
1 F1 0.856 5.4 >24
2 F2 0.924 5.9 >24
3 F3 0.845 7.0 >24
4 F4 0.916 5.0 >24
5 F5 0.924 5.2 >24
6 F6 0.933 4.8 >24
7 F7 0.856 4.9 >24
8 F8 0.867 5.2 >24
9 F9 0.886 3.0 12-24
10 F10 0.882 2.5 12-24
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hence from the above results it can be concluded that linear relationship exists
between swelling process and viscosity of polymer
Fig no – 7.16 Plot Showing Swelling Index of Metformin SR Tablets
7.3.4 Post Compression Parameters Metformin Tablets
The Tablets from each Metformin formulation were evaluated for Average
weight, Thickness, Hardness, Friability, weight variation and Uniformity in Drug
content. The results were reported in Table no: 7.8
Shape and description of the tablets
Physical examination of the tablets shows that the tablets were capsule shaped with
bisect on one side.
Tablet dimensions
The thickness of tablet was found to be in the range of 4.8  to 4.9 mm and was uniform
from F1 – F10
Hardness: The hardness of the tablets was found to be in the range of 6.0 ± 0.2 to 6.5 ±
0.4 kg/cm2 and was sufficient for the handling  of tablets throughout the shelf life.
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Friability
Percentage weight loss (or) % friability was measured and found to be in the range of
0.28 – 0.46 % and was within the pharmacopoeial limit that is less than 1% (F< 1%).
Weight variation test
The tablets of all the formulations (F1 – F10) passed the weight variation test as per
USP limits as they have shown less than 5% of deviation from their weight.
Drug content uniformity
Drug content of Metformin Hcl found to in the range of 98.94 ±0.42 to 101.03
±0.31%,was  within the limit as per I.P  and ICH  guidelines.
Table No -7.8 Results For Post Compression Parameters Of Metformin Tablet.
Formulation Average
Weight
mg  (n=20)
Hardness
Kg/cm2
(n=3)
Thickness
mm(n=3)
Friabi
lity%
(n=20)
Drug
Content
(%)
F1 645.03 ±1.64 6.2 ± 0.3 4.8 ± 0.07 0.58 101.03±0.31
F2 670.14 ±1.91 6.5 ± 0.6 4.9 ± 0.05 0.48 99.86 ±0.70
F3 695.06 ±1.02 6.3 ± 0.2 4.8 ± 0.11 0.36 99.27 ±1.02
F4 645.52 ±2.83 6.5 ± 0.2 4.8 ± 0.08 0.56 99.61 ±0.73
F5 695.05 ±1.61 6.4 ± 0.4 4.8 ± 0.08 0.53 99.83 ±0.41
F6 670.12 ±3.90 6.5 ± 0.3 4.8 ± 0.13 0.54 100.83±1.13
F7 695.05 ±1.24 6.3 ± 0.2 4.9 ± 0.15 0.39 98.94 ±0.42
F8 720.09 ±1.61 6.4 ± 0.2 4.8 ± 0.09 0.48 101.02 ±1.1
F9 710.08 ±1.02 6.0 ± 0.4 4.9 ± 0.07 0.51 99.57 ±0.7
F10 735.50 ±1.02 6.5 ± 0.4 4.9 ± 0.07 0.40 99.21 ±0.7
(± S.D) (S.D= Standard deviation)
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7.3.4 In Vitro Drug Release Study of Metformin Hcl Floating SR Layer Tablets
Table no – 7.9 Drug Release Profile of (F1- F5)
Fig No – 7.17 Plot Showing The Drug release Profile of F1- F5
Time in
hours
Cumulative percentage drug release
F1 F2 F3 F4 F5
0 0 0 0 0 0
1 35.23 30.11 28.46 33.38 30.23
2 52.62 47.15 43.65 50.29 48.66
4 69.24 59.61 57.62 67.24 62.46
6 82.36 72.48 70.54 79.56 74.41
8 91.74 81.69 79.52 88.32 83.62
10 97.03 89.54 87.35 98.63 89.65
12 94.85 91.25 94.57
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Table no- 7.10 Drug Release Profile of (F6- F8)
Time in hours Cumulative percentage drug release
F6 F7 F8
0 0 0 0
1 29.23 22.06 20.56
2 45.05 34.5 31.23
4 61.43 51.21 48.47
6 78.2 71.02 68.25
8 87.23 82.31 78.85
10 96.46 92.84 89.34
12 98.73 95.52
Fig No – 7.18 Graph Showing The Dissolution Profile Of F6- F8
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Table no – 7.11 Drug Release Profile of ( F9- F10 )
Fig No – 7.19 Graph Showing the Dissolution Profile of F9- F10
Time in hours Cumulative percentage drug release
F9 F10
0 0 0
1 30.35 35.05
2 46.12 48.44
4 58.65 60.05
6 74.24 77.31
8 82.21 84.20
10 89.36 91.65
12 93.52 96.75
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Table no – 7.1 Drug Release Profile of formulations F1 – F10
S
no
Time Cumulative  percentage Drug Release
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10
1 0 0 0 0 0 0 0 0 0 0 0
2 1 35.23 30.11 28.46 33.38 30.23 29.23 22.06 20.56 30.35 35.05
3 2 52.62 47.15 43.65 50.29 48.66 45.05 34.5 31.23 46.12 48.44
4 4 69.24 59.61 57.62 67.24 62.46 61.43 51.21 48.47 58.65 60.05
5 6 82.36 72.48 70.54 79.56 74.41 78.2 71.02 68.25 74.24 77.31
6 8 91.74 81.69 79.52 88.32 83.62 87.23 82.31 78.85 82.21 84.20
7 10 97.03 89.54 87.35 98.63 89.65 96.46 92.84 89.34 89.36 91.65
8 12 94.85 91.25 94.57 98.73 95.52 93.52 96.75
Fig no – 7.20: Comparative Drug Release Profile of F1 – F10
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 In the formulations FI – F3   HPMC K100M was used as the release retarding
polymer, being a hydrophilic swellable polymer it gradually swells with floating
and sustains the release of the drug up to 12 hrs. From F1 to F3 the drug release
rate decreases as the concentration of HPMC K100M increase from 100 mg to
150mg. In F1 as the concentration of HPMC K100M was 100 mg maximum
(97.03%) drug released in 10 hrs. Among F1, F2, F3 as the concentration of
HPMC K100M increases % drug release decreases.
 Further the trials were taken by taking sodium CMC as the rate retarding
polymer. Formulations F4, F5 having 100mg and 150 mg of sodium CMC
respectively shows less % drug release than same concentrations of HPMC K
100M .  From F4 to F5 as the viscosity of sodium CMC increases the drug
release decreases. In these formulations optimum drug release comparable to the
marketed tablets was not obtained at the end of 12 hrs.
 Further in formulations F6 to F8 high viscosity polymer HPMC K100M was
taken in combination with sodium CMC. Here HPMC concentration was kept
constant and sodium CMC was increased in the range of 3.7 % - 10.4% w/w.
 Freely soluble drugs have been reported to be released slower from
combinations of HPMC and Na CMC matrices than with HPMC alone, as the
combination increases the viscosity due to a synergistic effect of the two
polymers. Therefore in F6 – F8 as the concentration of sodium CMC increases
from 3.7 % - 10.4% w/w the cumulative % drug release decreases. Here F7
shows better drug release by releasing 98.73% at the end of 12 hrs.
 Then further trials were taken to determine the effect of increasing concentrations
of sodium bi-carbonate on floating lag time and % drug release. In  formulations
F9 to F10 as the concentration of sodium bicarbonate increases from 25 mg to
50 mg  floating lag time decreased from 4.5-5.0 min to 3.0 and 2.5 min
respectively.
 The drug release profile of F9 and F10 were compared with F3 having the same
composition, results shows increase in % drug release  by releasing  93.52 and
96.75 for F9  and F10 respectively when compared to F3 (91.25%).
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Hence, F7 was selected as the best formulation
7.3.5 Comparison of F7 with marketed formulation (GLUCOPHAGE XR).
Table no – 7.13 Comparision of F7 with Glucophage XR Tablets
Fig no – 7.20 Graph Showing Comparision Of F7 With GLUCOPHAGE XR
Marketed Formulation.
S no Time in hours Cumulative % drug release
F7 Glucophage SR
1 0 0 0
2 1 22.06 24.65
3 2 34.5 36.54
4 4 51.21 54.68
5 6 71.02 70.85
6 8 82.31 80.56
7 10 92.84 91.24
8 12 98.73 97.45
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7.4 EVALUATION OF SITAGLIPTIN IR TABLETS
7.4.1 Disintegration Test for Sitagliptin IR Tablets
Teble no – 7.14 Data Showing Disintegration Time For Sitagliptin IR tablets
S no Formulation Disintegration time (sec)
1 S1 98 ± 2.52
2 S2 75 ± 1.02
3 S3 58 ± 2.85
4 S4 92 ± 1.75
5 S5 69 ± 1.96
6 S6 56 ± 2.35
7 S7 84 ± 2.64
8 S8 59 ± 2.13
9 S9 54 ± 3.61
(n=3, ± S.D) (S.D= Standard deviation)
Disintegration time of the formulations S1 to S9 vary according to the varying
concentrations of superdisintegrants like crosspovidone and croscarmellose sodium.
From S1 to S3 as Crospovidone concentration increases from (2-5%) disintegration
time decreases gradually. Similarly from S4 – S6 as the concentration of Cros
Carmellose Sodium increases from (2-5%) disintegration time decreases
proportionally. Among the 2 superdisintegrants Croscarmellose Sodium gives less
disintegration time of 56 sec.
Further more in formulations S7 - S9 Sodium Starch Glycolate was used as the
superdisintegrants 2- 4%, as the concentration increases disintegration time decreases.
Among the three superdisintegrants used SSG was the better disintegrant showing
lesser DT time around 54 sec.
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7.4.2 Post Compression Parameters of Sitagliptin IR Tablets
Formulation Average
Weight
mg  (n=20)
Hardness
Kg/cm2
(n=3)
Thickness
mm(n=3)
Friabi
lity%
(n=20)
Drug
Content
(%)
S1 250.03 ±1.64 3.4 ± 0.3 2.8 ± 0.07 0.58 99.03±0.31
S2 251.14 ±1.91 3.3± 0.6 2.9 ± 0.05 0.48 99.86 ±0.70
S3 250.06 ±1.02 3.3 ± 0.2 2.8 ± 0.11 0.36 99.27 ±1.02
S4 250.52 ±2.83 3.5 ± 0.2 2.7 ± 0.08 0.56 101.61 ±0.73
S5 251.05 ±1.61 3.6 ± 0.4 2.8 ± 0.08 0.53 98.83 ±0.41
S6 249.12 ±3.90 3.4 ± 0.3 2.7 ± 0.13 0.54 100.83±1.13
S7 252.05 ±1.24 3.2 ± 0.2 2.9 ± 0.15 0.39 98.94 ±0.42
S8 250.09 ±1.61 3.3 ± 0.2 2.8 ± 0.09 0.48 97.56 ±1.1
S9 250.08 ±1.02 3.5 ± 0.4 2.9 ± 0.07 0.51 99.63 ±0.62
(± S.D) (S.D= Standard deviation)
Weight Variation Test
The weights of the tablets were between 249.12 to 252.05 mg. the acceptable weight
variation range is ±7.5%. Hence all tablets formulations passed the weight variation test.
Hardness
The hardness of all formulations was measured in kg/cm2. Hardness of all formulations
was in the ranged of 3.3 to 3.6 kg/ccm2.
Friability: The friability values of none of the formulations exceeded 1% the results
of friability indicate that the tablets were mechanically stable.
Thickness: Thickness of all the formulations was between 2.7 to 2.9 mm showings a
fairly uniform tabletting.
Drug content: Drug content was uniform ranging from 97.56 ±1.1to 101.61 ±0.73.
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7.4.3 In-Vitro Drug Release Profile of Sitagliptin IR Tablets
A) Drug Release profile of Sitagliptin IR Formulations SI – S3
Table no – 7.15 In Vitro Dissolution Profile of formulations (S1 – S3)
Fig No – 7.21 Graph Showing In Vitro Drug Release of (S1 – S3)
S no Time (min) Cumulative % drug release (% w/w)
S1 S2 S3
1 0 0 0 0
2 5 31.89 33.56 35.45
3 10 64.47 67.22 69.62
4 15 79.05 82.30 84.41
5 20 89.35 90.68 92.52
6 30 95.84 94.55 95.43
7 40 98.70 - -
8 60 - - -
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Table no - 7.16 In – Vitro Dissolution Profile For formulations (S4 – S6)
S no Time (min) Cumulative % drug release
S4 S5 S6
1 0 0 0 0
2 5 34.63 35.32 36.55
3 10 67.24 69.35 70.64
4 15 80.74 83.51 86.76
5 20 91.5 92.41 94.36
6 30 95.1 96.65 97.73
7 40 99.57 - -
8 60 - - -
Fig No – 7.22 Graph Showing In Vitro Drug Release of (S4 – S6)
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7.17 Table no - In – Vitro Dissolution Profile For formulations (S7 – S9)
S no Time (min) Cumulative % drug release
S7 S8 S9
1 0 0 0 0.00
2 5 35.47 37.22 38.55
3 10 68.61 70.36 72.64
4 15 85.73 88.65 89.64
5 20 90.12 95.37 97.86
6 30 94.24 97.64 99.64
7 40 - - -
8 60 - - -
Fig No – 7.23 Plot Showing In Vitro Drug Release of (S7 – S9)
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Table no – 7.18 Comparative Dissolution Profile for formulations (S1 – S9)
S no Time
min
Cumulative  percentage drug release
S1 S2 S3 S4 S5 S6 S7 S8 S9
1 0 0 0 0 0 0 0 0 0 0.00
2 5 31.89 33.56 35.45 34.63 35.32 36.55 35.47 37.22 38.55
3 10 64.47 67.22 69.62 67.24 69.35 70.64 68.61 70.36 72.64
4 15 79.05 82.30 84.41 80.74 83.51 86.76 85.73 88.65 89.64
5 20 89.35 90.68 92.52 91.5 92.41 94.36 90.12 95.37 97.86
6 30 95.84 94.55 95.43 95.1 96.65 97.73 94.24 97.64 99.64
7 40 98.70 - - 99.57 - - - - -
8 60 - - - - - - - - -
Fig no – 7.24 Comparative drug release Profile For Sitagliptin IR formulations
(S1- S9)
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Discussion
In the formulations S1 – S3 cross povidone was used as super disintegrant in
different proportions of 2%, 4%, 5% respectively. Therefore the drug release becomes
faster from S1 to S3 with S3 showing 95.43 % after 30 min. From S4 – S6 cross
carmellose sodium was used as super disintegrant in different proportions of 2-5%
respectively. Therefore the drug release becomes faster from S4 to S6 with S6
showing 97.73% after 30 min.
Thus from formulations S1 to S6 it can be inferred that cross carmellose sodium
was a better disintegrant giving faster release when compared to cross povidone. The
% drug release of 5% of CCS in formulation S6 was not comparable to the marketed
Sitagliptin IR tablets.
In formulations S7 – S9 sodium starch glycolate was used as the superdisintegrant 2-
4% accordingly the % drug release increases with S9 giving 99.64 % at the end of 30
min. Among the three superdisintegrants used SSG has shown better drug release
comparable to the marketed sitagliptin IR from JANUVIA 50mg.
Hence S9 was selected as best formulation of Sitagliptin IR Layer.
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7.45 Comparision Of best Sitagliptin IR formulation With Marketed tablets
Table no- 7.19 Comparision of S9 with Marketed (JANUVIA 50 mg)
S no Time (min) Cumulative % drug release
S9 JANUVIA
50 mg
1 0 0.00 0
2 5 38.55 41.65
3 10 72.64 75.17
4 15 89.64 91.42
5 20 97.86 97.52
6 30 99.64 98.64
7 40 - -
8 60 - -
Fig no – 7.2 Graph Showing Comparision of Drug Release Profile of S9
With Marketed Tablets
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7.5 EVALUATION OF BILAYER TABLETS
7.5.1 Floating Behaviour of the bi layer tablets
S.no Floating lag time
(n=5)  (± SD)
Total floating time
(n=5) (± SD)
Tablet density
(n=5) (± SD) (g/cc)
1 5.2 min > 24 hrs 0.846
( ± S.D) (S.D= Standard deviation)
7.5.2 Swelling Study
S no Time (hr) % Swelling Index
1 1 20.24
2 2 30.19
3 3 50.12
4 4 63.21
5 5 74.79
6 6 97.61
7.5.3 Disintegration test for Sitagliptin IR layer
S no Disintegration time (sec)  (n=6)  (avg± SD)
1 52 ± 2.5
( ± S.D) (S.D= Standard deviation)
7.5.4 Post compression parameters of the Bilayer tablets
Formulation Average
Weight
mg  (n=20)
(± SD)
Hardness
Kg/cm2(n
=3)
(± SD)
Thickness
mm(n=3)
(± SD)
Friabilit
y
%(n=20)
(± SD)
Drug content   (n=3)
Metformin
Hcl
Sitagliptin
Bi Layer
Tablet
(F7 + S9)
945.07
±1.38
6.7 ± 0.5 6.5 ± 0.63 0.75 99.67 ±0.42 99.63 ±0.7
( ± S.D) (S.D= Standard deviation)
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a) Shape and description of the tablets
Physical examination of the tablets shows that the bi - layered tablets were capsule
shaped with bisect on one side, With clear differentiation of the two layers with
colorless Metformin Hcl layer and sitagliptin layer having pale red colour.
b) Tablet dimensions
The thickness of tablets was found to be 6.5 ± 0.63 mm and was uniform in the batch.
c) Hardness
The hardness of the tablets was found to be 6.7 ± 0.5 kg/cm2 and was sufficient for the
handling throughout the shelf life.
d) Friability
Percentage weight loss (or) % Friability was measured and found to be in the range of
0.75 % and was within the pharmacopoeial limit that is less than 1% (F< 1%).
e) Weight Variation Test
The tablets of batch passed the weight variation test as per USP limits as they have
shown less than 5% of deviation from their weight.
f) Drug Content Uniformity
Drug contents of Metformin Hcl and Sitagliptin in the bilayered tablet were found to
99.67 ±0.42 and 99.63 ±0.7 respectively. For both drugs their drug contents were within
the limit as per I.P and ICH guidelines and have shown good content uniformity.
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7.5.5 In Vitro Drug Release Profile of The Bi - Layer Tablet
Table no -7.20: In Vitro Drug Release Profile of the Bi - Layered Tablet (S9 – F7)
S. no Time intervals Cumulative % drug release
Sitagliptin IR  S9 Metformin Hcl  F7
1 0 min 0.00 0
2 5 min 37.85 0.53
3 10 min 72.05 2.36
4 15 min 88.64 5.42
5 20 min 97.20 8.37
6 30 min 99.15 13.56
7 40 min 100.10 19.34
8 60 min - 21.56
9 2   h - 33.75
10 4   h - 52.40
11 6   h - 71.02
12 8   h - 81.31
13 10 h - 92.20
14 12 h - 97.65
Fig no – 7.25: In Vitro Drug Release Profile of the BiLayered Tablet
(S9 – F7)
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Table no -7.21 Comparision of drug release from bilayer tablet with
marketed formulations
S
no
Time
intervals
Cumulative percentage  drug release
S9 JANUVIA
50 mg
F7 GLUCOPHAGE
XR 500 mg
1 0 min 0.00 0 0.00 -
2 5 min 37.85 41.65 0.53 -
3 10 min 72.05 75.17 2.36 -
4 15 min 88.64 91.42 5.42 -
5 20 min 97.20 97.52 8.37 -
6 30 min 99.15 98.64 13.56 -
7 40 min 100.10 - 19.34 -
8 60 min 100.32 - 21.56 24.65
9 2   h 100.33 - 33.75 36.54
10 4   h 100.46 - 52.40 54.68
11 6   h 100.39 - 71.02 70.85
12 8   h 101.32 - 81.31 80.56
13 10 h 101.35 - 92.20 91.24
14 12 h 101.38 - 97.65 97.45
7.6 Kinetic study for Metformin SR layer of Bilayer Tablet
Evaluation of mechanism of drug release was done for the Metformin Hcl floating
SR layer of the bi layer tablet (F7). In vitro drug release date was fitted into various
kinetic models
A) Zero order : Graph of cumulative percentage of drug released and time
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B) First order : Graph of log cumulative percentage of drug remaining and
time.
C) Higuchi model :
Graph of cumulative percentage drug release and square root of time
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D) Korsmeyer – peppas model :
Graph of log cumulative percentage drug release and log time.
Table No – 7.22: Data for Kinetic Studies
S
no
Time Log T %
CDR
log %
CDR
Cum %
drug
remained
Log %
cum drug
remained
1 0 0 0 0 0 0 0
2 1 1.00 0 22.06 1.343 77.94 1.891
3 2 1.414 0.3010 34.5 1.537 65.50 1.816
4 4 2.00 0.602 51.21 1.709 48.90 1.689
5 6 2.44 0.7781 71.02 1.851 28.98 1.462
6 8 2.848 0.903 82.31 1.915 17.68 1.247
7 10 3.162 1.00 92.84 1.967 7.16 0.854
8 12 3.464 1.0791 98.73 1.994 1.27 0.103
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Table no – 7.23 Results of kimetic studies for optimized formulation F7
S
no
Formul
ation
Zero
order
R2
First
order
R2
Higuchi
R2
Koresmeyer
peppas  R2
n Mechanism
of drug
release
1 F7 0.947 0.978 0.991 0.633 0.617 First order
non fickian
diffusion
Mechanism of drug release
In order to understand the complex mechanism of drug release from the SR
matrix system, the % in vitro release was fitted into Korsmeyer-peppas model and the
release exponent value (n) was interpreted for mechanism of drug release. The release
exponent value (n) thus obtained was 0.617 therefore, we can conclude that it follows
Non Fickian Diffusion mechanism. The F 7 formulation exhibited First order,
Higuchi mechanism.
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7.7 Stability Studies
Stability studies
The selected formulation was evaluated for stability by conducting accelerated
stability studies. The formulation were stored at 40o C at 75% RH for 3 months and
analyzed for their physical parameters and drug content and in vitro drug release studies
at every one month interval. The data were shown in the table no 7.23.
Table No – 7.24:Characteristics of bi layered Tablet during stability studies
Time interval Drug content (%w/w) Hardness
(Kg/cm2)
Friability
(%)Metformin
Hcl
Sitagliptin
After one
month
99.68±0.42 99.63 ±0.62 6.60 ± 0.64 0.31
After two
months
98.90 ± 0.12 99.35 ±0.45 6.50 ± 0.55 0.31
After three
months
98.45 ± 0.08 98.94 ±0.67 6.5 ± 0.43 0.32
( ± S.D n = 3) (S.D= Standard deviation)
Table No –7. 25: In vitro drug release profile of Metformin Hcl layer
Time in
hours
Cumulative % drug release
1st Month 2nd Month 3rd Month
0 0.00 0.00 0.00
1 22.06 22.25 22.3
2 34.5 33.75 33.90
4 51.21 50.80 50.55
6 71.02 70.84 70.43
8 82.31 82.07 81.75
10 92.84 92.41 92.06
12 98.73 98.26 98.05
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Table No –7. 26: In Vitro Drug release profile of  Sitagliptin layer
Time in
hours
Cumulative % Drug Release
1st Month 2nd Month 3rd Month
0 0 0 0
5 38.46 38.32 38.85
10 72.60 72.05 71.95
15 89.54 89.25 89.20
20 97.72 97.05 97.04
30 99.44 99.20 99.15
40
THE PREPARED BILAYER TABLETS
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9. CONCLUSION
In the present study an attempt was made to design a combination bi layer
tablet containing Metformin Hcl gastro retentive floating sustained release layer and
Sitagliptin immediate release layer.
FT - IR studies reveal that there were no significant interactions between both
the drugs and between the drugs and their respective excipients.
For achieving sustained release of Metformin two hydrophilic swellable
polymers like HPMC K100M and sodium CMC were used. Here, F7 containing
combination of both polymers gave better sustained release for 12 hrs when
compared to individual polymers. Formulation F7 gave 98.73 % W/V drug release
after 12 hrs. Therefore F7 was selected as best formulation among F1-F10 and it is
comparable to marketed Metformin tablets (GLUCOPGAGE XR).
For achieving immediate release of Sitagliptin, From the results it was
concluded that disintegration activity decreases in the order of Cross Povidone <
Cross Carmellose Sodium < Sodium Starch Glycolate i.e from S1 to S9
disintegration time decreases and % cumulative drug release increases. Thus S9
releasing 99.86 % after 30 min was selected as best formulation and is comparable
to the marketed Sitagliptin tablets (JANUVIA).
Good floating behaviour was achieved by using sodium bicarbonate. In
formulations F9-F10 as the concentration of sodium bicarbonate was increased the
floating lag time decreased with minimal decrease in total floating time and % drug
release increased when compared to F3 having same concentration of HPMC
K100M.
The bilayer tablets prepared by taking F7 and S9 as two layers have shown
good floating behaviour, good post compression parameters like hardness, friability
weight variation drug content etc which were within the limits. Both the drugs in
bilayer tablets shown dissolution profiles comparable with that of their respective
marketed tablets.
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Since, HPMC is a good hydrophilic polymer which ensures integrity of the gel
layer causing slow diffusion of the drug through matrix. The combination of HPMC
K100M and Sodium CMC gave good sustained drug release for 12 hrs when
compared to HPMC alone due to increase in the viscosity by synergistic effect of the
two polymers.
From this study by preparing bilayer tablets, it was concluded that we could
reduce the total dose, dosage frequency, dose related side effects, and improve the
bioavailability of Metformin which in turn improves the patient compliance.
Thus a fixed dose combination tablet of Metformin and Sitagliptin were
designed as bilayer tablets which will have good patient compliance over their
individual marketed counterparts.
However, further clinical studies are needed to access the utility of this
system.
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